{"id": "article-151525_0", "title": "Sympathetic Ophthalmia -- Continuing Education Activity", "content": "Sympathetic ophthalmia is a rare, devastating disease defined as bilateral uveitis following an eye injury.\u00a0The condition may result in permanent bilateral vision loss in an otherwise healthy patient with no ocular morbidities. Initial symptoms and the timeline for the onset of symptoms after an injury are highly variable. Therefore, sympathetic ophthalmia must be considered\u00a0within the differential\u00a0for any presentation of bilateral uveitis. Managing this disease\u00a0is\u00a0challenging, requiring several immunosuppressants as part of treatment. Sympathetic ophthalmia is an uncommon, systemic uveitis that develops as a granulomatous inflammation in both eyes after an injury or invasive procedure. Typically emerging within the first 12 months post-injury,\u00a0the onset can be postponed for several years. This condition is characterized by granulomatous inflammation with distinctive choroidal yellow-white nodules. Early treatment usually involves high doses of corticosteroids, which can elicit a prompt response; however, sustaining the remission often necessitates continuous immunomodulatory agents to curb further flare-ups.", "contents": "Sympathetic Ophthalmia -- Continuing Education Activity. Sympathetic ophthalmia is a rare, devastating disease defined as bilateral uveitis following an eye injury.\u00a0The condition may result in permanent bilateral vision loss in an otherwise healthy patient with no ocular morbidities. Initial symptoms and the timeline for the onset of symptoms after an injury are highly variable. Therefore, sympathetic ophthalmia must be considered\u00a0within the differential\u00a0for any presentation of bilateral uveitis. Managing this disease\u00a0is\u00a0challenging, requiring several immunosuppressants as part of treatment. Sympathetic ophthalmia is an uncommon, systemic uveitis that develops as a granulomatous inflammation in both eyes after an injury or invasive procedure. Typically emerging within the first 12 months post-injury,\u00a0the onset can be postponed for several years. This condition is characterized by granulomatous inflammation with distinctive choroidal yellow-white nodules. Early treatment usually involves high doses of corticosteroids, which can elicit a prompt response; however, sustaining the remission often necessitates continuous immunomodulatory agents to curb further flare-ups."}
{"id": "article-151525_1", "title": "Sympathetic Ophthalmia -- Continuing Education Activity", "content": "Participating in\u00a0this course equips clinicians with comprehensive knowledge of sympathetic ophthalmia, including its diverse clinical presentations and management strategies. Through collaborative learning, clinicians understand the importance of early diagnosis and tailored treatment plans to prevent irreversible vision impairment. Interprofessional teamwork enhances patient outcomes by facilitating holistic care and integrating ophthalmological expertise with immunological insights. By fostering effective communication and collaboration among specialists, the course empowers healthcare professionals to deliver timely interventions, optimize treatment regimens, and improve overall prognosis for patients with sympathetic ophthalmia.", "contents": "Sympathetic Ophthalmia -- Continuing Education Activity. Participating in\u00a0this course equips clinicians with comprehensive knowledge of sympathetic ophthalmia, including its diverse clinical presentations and management strategies. Through collaborative learning, clinicians understand the importance of early diagnosis and tailored treatment plans to prevent irreversible vision impairment. Interprofessional teamwork enhances patient outcomes by facilitating holistic care and integrating ophthalmological expertise with immunological insights. By fostering effective communication and collaboration among specialists, the course empowers healthcare professionals to deliver timely interventions, optimize treatment regimens, and improve overall prognosis for patients with sympathetic ophthalmia."}
{"id": "article-151525_2", "title": "Sympathetic Ophthalmia -- Continuing Education Activity", "content": "Objectives: Identify the clinical features and risk factors associated with sympathetic ophthalmia. Differentiate sympathetic ophthalmia from other forms of uveitis based on clinical presentation and history of ocular trauma. Screen patients presenting with bilateral uveitis for signs suggestive of sympathetic ophthalmia, utilizing appropriate diagnostic tests. Implement\u00a0early identification of sympathetic ophthalmia within an interprofessional team to enhance patient outcomes. Access free multiple choice questions on this topic.", "contents": "Sympathetic Ophthalmia -- Continuing Education Activity. Objectives: Identify the clinical features and risk factors associated with sympathetic ophthalmia. Differentiate sympathetic ophthalmia from other forms of uveitis based on clinical presentation and history of ocular trauma. Screen patients presenting with bilateral uveitis for signs suggestive of sympathetic ophthalmia, utilizing appropriate diagnostic tests. Implement\u00a0early identification of sympathetic ophthalmia within an interprofessional team to enhance patient outcomes. Access free multiple choice questions on this topic."}
{"id": "article-151525_3", "title": "Sympathetic Ophthalmia -- Introduction", "content": "Sympathetic ophthalmia is a rare pathologic process characterized by bilateral uveitis following injury to\u00a01 eye either from surgery or penetrating ocular trauma. [1] Though this is a rare process,\u00a0the condition\u00a0is serious\u00a0and can\u00a0cause blindness in the injured eye (ie, the inciting eye) and the contralateral eye (ie, the sympathizing eye). The onset of symptoms typically occurs within\u00a01\u00a0year of injury\u00a0but\u00a0can\u00a0occur up to 66 years\u00a0after\u00a0the initial injury. [2] Sympathetic ophthalmia, often called sympathetic uveitis, is an uncommon and severe eye condition triggered by an immune system response. This inflammation impacts both eyes following trauma or surgery to\u00a01 eye, especially when uveal tissue is involved. [3]", "contents": "Sympathetic Ophthalmia -- Introduction. Sympathetic ophthalmia is a rare pathologic process characterized by bilateral uveitis following injury to\u00a01 eye either from surgery or penetrating ocular trauma. [1] Though this is a rare process,\u00a0the condition\u00a0is serious\u00a0and can\u00a0cause blindness in the injured eye (ie, the inciting eye) and the contralateral eye (ie, the sympathizing eye). The onset of symptoms typically occurs within\u00a01\u00a0year of injury\u00a0but\u00a0can\u00a0occur up to 66 years\u00a0after\u00a0the initial injury. [2] Sympathetic ophthalmia, often called sympathetic uveitis, is an uncommon and severe eye condition triggered by an immune system response. This inflammation impacts both eyes following trauma or surgery to\u00a01 eye, especially when uveal tissue is involved. [3]"}
{"id": "article-151525_4", "title": "Sympathetic Ophthalmia -- Introduction", "content": "The eye experiencing the initial trauma or surgery\u00a0is called\u00a0the\u00a0\"inciting\"\u00a0eye, while the other, affected eye is termed the\u00a0\"sympathizing\"\u00a0eye. The onset of symptoms can occur anytime from a few days to many years post-injury, but most cases appear within\u00a01\u00a0year of the inciting event. Historically, younger individuals were more frequently affected due to accidental injuries. Still, recent reports suggest an increased occurrence in older adults, possibly linked to the higher rates of ocular surgeries in this demographic. [4] Sympathetic ophthalmia, although rare, carries a significant risk of causing vision loss in both eyes. The exact pathogenesis of sympathetic ophthalmia is unclear.\u00a0The\u00a0immune-privileged status of the eye occurs after a penetrating injury and exposure of previously sequestered uveoretinal antigens to the systemic immune system. The resulting inflammation in the eye\u00a0is devastating and causes permanent blindness. Therefore, early detection and intervention with immunosuppression are vital. [5]", "contents": "Sympathetic Ophthalmia -- Introduction. The eye experiencing the initial trauma or surgery\u00a0is called\u00a0the\u00a0\"inciting\"\u00a0eye, while the other, affected eye is termed the\u00a0\"sympathizing\"\u00a0eye. The onset of symptoms can occur anytime from a few days to many years post-injury, but most cases appear within\u00a01\u00a0year of the inciting event. Historically, younger individuals were more frequently affected due to accidental injuries. Still, recent reports suggest an increased occurrence in older adults, possibly linked to the higher rates of ocular surgeries in this demographic. [4] Sympathetic ophthalmia, although rare, carries a significant risk of causing vision loss in both eyes. The exact pathogenesis of sympathetic ophthalmia is unclear.\u00a0The\u00a0immune-privileged status of the eye occurs after a penetrating injury and exposure of previously sequestered uveoretinal antigens to the systemic immune system. The resulting inflammation in the eye\u00a0is devastating and causes permanent blindness. Therefore, early detection and intervention with immunosuppression are vital. [5]"}
{"id": "article-151525_5", "title": "Sympathetic Ophthalmia -- Introduction", "content": "The clinical presentation can vary, with symptoms typically developing weeks to months after the initial injury. In some cases, the onset\u00a0is delayed for years, leading to challenges in diagnosis. Common symptoms include decreased vision, eye redness, pain, and sensitivity to light. Upon examination, ophthalmologists may find signs such as inflammation in the vitreous and anterior chamber, choroidal lesions, and, in some cases, the characteristic Dalen-Fuchs nodules, accumulations of inflammatory cells beneath the retina. [6] Sympathetic ophthalmia is primarily diagnosed through clinical findings and the history of trauma or surgery to the eye. Ancillary tests such as ocular imaging and laboratory investigations can support the diagnosis but are not definitive. The importance of early detection and treatment cannot\u00a0be overstated, as timely management can significantly alter the disease course. [7]", "contents": "Sympathetic Ophthalmia -- Introduction. The clinical presentation can vary, with symptoms typically developing weeks to months after the initial injury. In some cases, the onset\u00a0is delayed for years, leading to challenges in diagnosis. Common symptoms include decreased vision, eye redness, pain, and sensitivity to light. Upon examination, ophthalmologists may find signs such as inflammation in the vitreous and anterior chamber, choroidal lesions, and, in some cases, the characteristic Dalen-Fuchs nodules, accumulations of inflammatory cells beneath the retina. [6] Sympathetic ophthalmia is primarily diagnosed through clinical findings and the history of trauma or surgery to the eye. Ancillary tests such as ocular imaging and laboratory investigations can support the diagnosis but are not definitive. The importance of early detection and treatment cannot\u00a0be overstated, as timely management can significantly alter the disease course. [7]"}
{"id": "article-151525_6", "title": "Sympathetic Ophthalmia -- Introduction", "content": "Treatment typically begins with high doses of corticosteroids to suppress the immune response and control inflammation. Due to the chronic nature of sympathetic ophthalmia, many patients require long-term immunosuppression to maintain control of the inflammation and preserve vision.\u00a0This\u00a0often necessitates the use of steroid-sparing agents like methotrexate, azathioprine, or biologic drugs. The risk factors for developing\u00a0this condition include the nature of the trauma, the extent of uveal tissue exposure, and possibly genetic predispositions. [8] Given\u00a0the potential severity, prevention is a\u00a0key\u00a0aspect of management in ocular trauma and surgery, with meticulous surgical techniques to avoid uveal tissue exposure and prompt, aggressive treatment of any postoperative inflammation. Understanding\u00a0sympathetic ophthalmia\u00a0has evolved with advances in immunology and ocular imaging yet remains an active research area. Studies continue to seek better ways to predict who is at risk, how to prevent\u00a0the development, and how to optimize long-term management to prevent recurrences and preserve vision.", "contents": "Sympathetic Ophthalmia -- Introduction. Treatment typically begins with high doses of corticosteroids to suppress the immune response and control inflammation. Due to the chronic nature of sympathetic ophthalmia, many patients require long-term immunosuppression to maintain control of the inflammation and preserve vision.\u00a0This\u00a0often necessitates the use of steroid-sparing agents like methotrexate, azathioprine, or biologic drugs. The risk factors for developing\u00a0this condition include the nature of the trauma, the extent of uveal tissue exposure, and possibly genetic predispositions. [8] Given\u00a0the potential severity, prevention is a\u00a0key\u00a0aspect of management in ocular trauma and surgery, with meticulous surgical techniques to avoid uveal tissue exposure and prompt, aggressive treatment of any postoperative inflammation. Understanding\u00a0sympathetic ophthalmia\u00a0has evolved with advances in immunology and ocular imaging yet remains an active research area. Studies continue to seek better ways to predict who is at risk, how to prevent\u00a0the development, and how to optimize long-term management to prevent recurrences and preserve vision."}
{"id": "article-151525_7", "title": "Sympathetic Ophthalmia -- Introduction", "content": "Sympathetic ophthalmia\u00a0is an enigmatic and potentially devastating condition that encapsulates the intricate interplay between the ocular tissues and the immune system.\u00a0The capacity to affect vision dramatically shows the importance of preventive strategies during ocular surgery, the necessity for vigilance in the face of ocular trauma, and the evolving landscape of immunomodulatory therapies in ophthalmology. [9]", "contents": "Sympathetic Ophthalmia -- Introduction. Sympathetic ophthalmia\u00a0is an enigmatic and potentially devastating condition that encapsulates the intricate interplay between the ocular tissues and the immune system.\u00a0The capacity to affect vision dramatically shows the importance of preventive strategies during ocular surgery, the necessity for vigilance in the face of ocular trauma, and the evolving landscape of immunomodulatory therapies in ophthalmology. [9]"}
{"id": "article-151525_8", "title": "Sympathetic Ophthalmia -- Etiology", "content": "First coined by William Mackenzie in 1840, sympathetic ophthalmia refers to bilateral ocular inflammation secondary to unilateral eye trauma or surgery. [10] Classically,\u00a0sympathetic ophthalmia\u00a0is defined as a bilateral diffuse granulomatous panuveitis\u00a0that presents with mutton fat keratitic precipitates. However, patient presentations of sympathetic ophthalmia may significantly vary in inflammation on presentation.", "contents": "Sympathetic Ophthalmia -- Etiology. First coined by William Mackenzie in 1840, sympathetic ophthalmia refers to bilateral ocular inflammation secondary to unilateral eye trauma or surgery. [10] Classically,\u00a0sympathetic ophthalmia\u00a0is defined as a bilateral diffuse granulomatous panuveitis\u00a0that presents with mutton fat keratitic precipitates. However, patient presentations of sympathetic ophthalmia may significantly vary in inflammation on presentation."}
{"id": "article-151525_9", "title": "Sympathetic Ophthalmia -- Etiology", "content": "Per the Standardization of Uveitis Nomenclature (SUN) working group definition in 2021, the diagnosis criteria for sympathetic ophthalmia are as follows: (1) history of unilateral ocular trauma or surgery AND (2) ocular inflammation in both eyes or, if the inciting eye has no view, detectable inflammation in the sympathizing eye AND (3) either anterior uveitis with vitreous inflammation OR panuveitis with choroidal involvement. [1]", "contents": "Sympathetic Ophthalmia -- Etiology. Per the Standardization of Uveitis Nomenclature (SUN) working group definition in 2021, the diagnosis criteria for sympathetic ophthalmia are as follows: (1) history of unilateral ocular trauma or surgery AND (2) ocular inflammation in both eyes or, if the inciting eye has no view, detectable inflammation in the sympathizing eye AND (3) either anterior uveitis with vitreous inflammation OR panuveitis with choroidal involvement. [1]"}
{"id": "article-151525_10", "title": "Sympathetic Ophthalmia -- Etiology", "content": "Penetrating ocular trauma and vitreoretinal surgeries\u00a0cause the highest risk of developing sympathetic ophthalmia. [11] However, cases of sympathetic ophthalmia have\u00a0been reported\u00a0with cataract surgery, glaucoma surgery, intravitreal injections,\u00a0cyclodestructive\u00a0procedures, choroidal melanoma radiation therapy, and pan-retinal photocoagulation. [12] [13] [14] [15]", "contents": "Sympathetic Ophthalmia -- Etiology. Penetrating ocular trauma and vitreoretinal surgeries\u00a0cause the highest risk of developing sympathetic ophthalmia. [11] However, cases of sympathetic ophthalmia have\u00a0been reported\u00a0with cataract surgery, glaucoma surgery, intravitreal injections,\u00a0cyclodestructive\u00a0procedures, choroidal melanoma radiation therapy, and pan-retinal photocoagulation. [12] [13] [14] [15]"}
{"id": "article-151525_11", "title": "Sympathetic Ophthalmia -- Etiology -- Triggering Events", "content": "Trauma Surgical intervention Other ocular pathologies [16] [17]", "contents": "Sympathetic Ophthalmia -- Etiology -- Triggering Events. Trauma Surgical intervention Other ocular pathologies [16] [17]"}
{"id": "article-151525_12", "title": "Sympathetic Ophthalmia -- Etiology -- Trauma", "content": "Open globe injury Closed globe injury Chemical injury Thermal injury [18]", "contents": "Sympathetic Ophthalmia -- Etiology -- Trauma. Open globe injury Closed globe injury Chemical injury Thermal injury [18]"}
{"id": "article-151525_13", "title": "Sympathetic Ophthalmia -- Etiology -- Surgical Intervention", "content": "Gunderson flap Cataract surgery Penetrating keratoplasty Glaucoma surgery Para plana vitrectomy Diode cyclophotocoagulation Scleral buckle Intravitreal injections Enucleation Evisceration Treatment of choroidal melanoma with proton bean Iridectomy Iridenclesis Iris\u00a0incarceration in wound Paracentesis Phakic intraocular lens implantation [19] [20] [21] [22] [23] [24]", "contents": "Sympathetic Ophthalmia -- Etiology -- Surgical Intervention. Gunderson flap Cataract surgery Penetrating keratoplasty Glaucoma surgery Para plana vitrectomy Diode cyclophotocoagulation Scleral buckle Intravitreal injections Enucleation Evisceration Treatment of choroidal melanoma with proton bean Iridectomy Iridenclesis Iris\u00a0incarceration in wound Paracentesis Phakic intraocular lens implantation [19] [20] [21] [22] [23] [24]"}
{"id": "article-151525_14", "title": "Sympathetic Ophthalmia -- Etiology -- Ocular Pathologies", "content": "Fungal keratitis Bacterial keratitis Acanthamoeba keratitis", "contents": "Sympathetic Ophthalmia -- Etiology -- Ocular Pathologies. Fungal keratitis Bacterial keratitis Acanthamoeba keratitis"}
{"id": "article-151525_15", "title": "Sympathetic Ophthalmia -- Epidemiology", "content": "A commonly cited general incidence of sympathetic ophthalmia is around 0.03 per 100,000 persons per year. [11] A retrospective analysis of sympathetic ophthalmia cases demonstrated around 62.7% of cases are secondary to accidental injury, and 34.5% are secondary to surgical trauma. [25] The incidence of patients developing sympathetic ophthalmia after traumatic eye injury was 0.19%.\u00a0The incidence of patients developing disease following vitreoretinal surgery was significantly lower, around 0.038%.\u00a0Repeated inciting events, especially patients with repeated traumatic injuries, are at the greatest risk of developing sympathetic ophthalmia.", "contents": "Sympathetic Ophthalmia -- Epidemiology. A commonly cited general incidence of sympathetic ophthalmia is around 0.03 per 100,000 persons per year. [11] A retrospective analysis of sympathetic ophthalmia cases demonstrated around 62.7% of cases are secondary to accidental injury, and 34.5% are secondary to surgical trauma. [25] The incidence of patients developing sympathetic ophthalmia after traumatic eye injury was 0.19%.\u00a0The incidence of patients developing disease following vitreoretinal surgery was significantly lower, around 0.038%.\u00a0Repeated inciting events, especially patients with repeated traumatic injuries, are at the greatest risk of developing sympathetic ophthalmia."}
{"id": "article-151525_16", "title": "Sympathetic Ophthalmia -- Epidemiology", "content": "The average age\u00a0of presentation for sympathetic ophthalmia\u00a0is usually between 40 and 45. [26] [27] [28] Several studies have also\u00a0suggested a gender predilection, with\u00a0men having sympathetic ophthalmia at higher rates than women. [29] [30] The timeline for the onset of inflammation after trauma or surgery can vary from weeks to decades after the inciting event, with the most significant risk period being within\u00a01 year. 50% of patients\u00a0have onset of symptoms within\u00a03 months, and 90% of patients within\u00a01 year. [31] Notably, a reported case of sympathetic ophthalmia began 66 years after the inciting traumatic injury. [2]", "contents": "Sympathetic Ophthalmia -- Epidemiology. The average age\u00a0of presentation for sympathetic ophthalmia\u00a0is usually between 40 and 45. [26] [27] [28] Several studies have also\u00a0suggested a gender predilection, with\u00a0men having sympathetic ophthalmia at higher rates than women. [29] [30] The timeline for the onset of inflammation after trauma or surgery can vary from weeks to decades after the inciting event, with the most significant risk period being within\u00a01 year. 50% of patients\u00a0have onset of symptoms within\u00a03 months, and 90% of patients within\u00a01 year. [31] Notably, a reported case of sympathetic ophthalmia began 66 years after the inciting traumatic injury. [2]"}
{"id": "article-151525_17", "title": "Sympathetic Ophthalmia -- Epidemiology", "content": "Gomi and colleagues have indicated that sympathetic ophthalmia accounts for approximately 0.3% of all uveitis presentations. Further research posits that the incidence could range between 0.2% and 1% following penetrating ocular injuries and around 0.01% after intraocular surgical procedures.\u00a0Liddy and Stuart observed that\u00a0sympathetic ophthalmia\u00a0manifested in 0.2% of non-surgically inflicted ocular injuries, distinguishing that 0.19% resulted from penetrating trauma and a mere 0.007% post intraocular surgery. Holland\u2019s findings denote that sympathetic ophthalmia occurs in 0.5% of ocular trauma cases. Gass and colleagues noted a prevalence of 0.01% after standard pars plana vitrectomy, which escalated to 0.06% when the vitrectomy was associated with penetrating trauma. [32]", "contents": "Sympathetic Ophthalmia -- Epidemiology. Gomi and colleagues have indicated that sympathetic ophthalmia accounts for approximately 0.3% of all uveitis presentations. Further research posits that the incidence could range between 0.2% and 1% following penetrating ocular injuries and around 0.01% after intraocular surgical procedures.\u00a0Liddy and Stuart observed that\u00a0sympathetic ophthalmia\u00a0manifested in 0.2% of non-surgically inflicted ocular injuries, distinguishing that 0.19% resulted from penetrating trauma and a mere 0.007% post intraocular surgery. Holland\u2019s findings denote that sympathetic ophthalmia occurs in 0.5% of ocular trauma cases. Gass and colleagues noted a prevalence of 0.01% after standard pars plana vitrectomy, which escalated to 0.06% when the vitrectomy was associated with penetrating trauma. [32]"}
{"id": "article-151525_18", "title": "Sympathetic Ophthalmia -- Epidemiology", "content": "A\u00a0higher predilection\u00a0exists for post-traumatic sympathetic ophthalmia in men, with incidence rates being 1.8-fold greater in comparison to women\u2014likely linked to greater exposure to occupational risks and a predominance of outdoor activities. Conversely, the incidence rate of post-surgical sympathetic ophthalmia is analogous between the sexes, with recent trends indicating a rise in cases. Castiblanco and team found that post-surgical events contribute to 44% of sympathetic ophthalmia cases, with 21% arising after pars plana vitrectomy. A recurrent theme in these occurrences is the presence of a penetrating injury that leads to complex wound-healing challenges, often compounded by the entrapment of ocular structures such as the iris, ciliary body, or choroid. [33]", "contents": "Sympathetic Ophthalmia -- Epidemiology. A\u00a0higher predilection\u00a0exists for post-traumatic sympathetic ophthalmia in men, with incidence rates being 1.8-fold greater in comparison to women\u2014likely linked to greater exposure to occupational risks and a predominance of outdoor activities. Conversely, the incidence rate of post-surgical sympathetic ophthalmia is analogous between the sexes, with recent trends indicating a rise in cases. Castiblanco and team found that post-surgical events contribute to 44% of sympathetic ophthalmia cases, with 21% arising after pars plana vitrectomy. A recurrent theme in these occurrences is the presence of a penetrating injury that leads to complex wound-healing challenges, often compounded by the entrapment of ocular structures such as the iris, ciliary body, or choroid. [33]"}
{"id": "article-151525_19", "title": "Sympathetic Ophthalmia -- Pathophysiology -- The Mechanism of Pathology", "content": "The precise pathophysiology of sympathetic ophthalmia is not clearly understood; however, most evidence points to an autoimmune inflammatory process secondary to ocular injury following trauma or surgery. [34] The eye is\u00a0an immune-privileged space in the body where systemic immune responses to antigens are markedly reduced. This is achieved by the absence of intraocular lymphatics and tight junctions in the retinal pigment epithelium, creating\u00a0the blood-retina barrier. [35] Disruption of this system in penetrating injuries results in exposure of previously sequestered ocular antigens to local conjunctival lymphatics, activating cell-mediated immunity and a type IV delayed hypersensitivity reaction. [36]", "contents": "Sympathetic Ophthalmia -- Pathophysiology -- The Mechanism of Pathology. The precise pathophysiology of sympathetic ophthalmia is not clearly understood; however, most evidence points to an autoimmune inflammatory process secondary to ocular injury following trauma or surgery. [34] The eye is\u00a0an immune-privileged space in the body where systemic immune responses to antigens are markedly reduced. This is achieved by the absence of intraocular lymphatics and tight junctions in the retinal pigment epithelium, creating\u00a0the blood-retina barrier. [35] Disruption of this system in penetrating injuries results in exposure of previously sequestered ocular antigens to local conjunctival lymphatics, activating cell-mediated immunity and a type IV delayed hypersensitivity reaction. [36]"}
{"id": "article-151525_20", "title": "Sympathetic Ophthalmia -- Pathophysiology -- The Mechanism of Pathology", "content": "Though no singular culprit has been identified as the antigen responsible for sympathetic ophthalmia, several ocular antigens have been implicated, including arrestin (S-antigen), recoverin, rhodopsin, melanocyte-associated tyrosinase, interphotoreceptor retinoid-binding protein, and retinal pigment epithelium associated antigens. These have been studied in animal models and shown to produce autoimmune uveitic reactions that mimic sympathetic ophthalmia. [37] [38] [39] [40] Genetic predisposition\u00a0to sympathetic ophthalmia is another emerging area of research, enabling the identification of at-risk patient populations. Human leukocyte antigen (HLA)-DR4, HLA-A11, and HLA-B40 are associated with sympathetic ophthalmia. [41]", "contents": "Sympathetic Ophthalmia -- Pathophysiology -- The Mechanism of Pathology. Though no singular culprit has been identified as the antigen responsible for sympathetic ophthalmia, several ocular antigens have been implicated, including arrestin (S-antigen), recoverin, rhodopsin, melanocyte-associated tyrosinase, interphotoreceptor retinoid-binding protein, and retinal pigment epithelium associated antigens. These have been studied in animal models and shown to produce autoimmune uveitic reactions that mimic sympathetic ophthalmia. [37] [38] [39] [40] Genetic predisposition\u00a0to sympathetic ophthalmia is another emerging area of research, enabling the identification of at-risk patient populations. Human leukocyte antigen (HLA)-DR4, HLA-A11, and HLA-B40 are associated with sympathetic ophthalmia. [41]"}
{"id": "article-151525_21", "title": "Sympathetic Ophthalmia -- Pathophysiology -- The Mechanism of Pathology", "content": "More recent studies have\u00a0demonstrated that the expression of HLA-DRB1*04 and HLA-DQA1*03 is significantly associated with sympathetic ophthalmia across white and Japanese patients. [42] [43] Accidental penetrating injuries and iatrogenic surgical trauma are the primary precursors in 60% to 70% and 30% of sympathetic ophthalmia cases, respectively. Historically considered exacerbated by infectious agents, current understanding confirms that\u00a0the condition predominantly arises without intraocular infection.", "contents": "Sympathetic Ophthalmia -- Pathophysiology -- The Mechanism of Pathology. More recent studies have\u00a0demonstrated that the expression of HLA-DRB1*04 and HLA-DQA1*03 is significantly associated with sympathetic ophthalmia across white and Japanese patients. [42] [43] Accidental penetrating injuries and iatrogenic surgical trauma are the primary precursors in 60% to 70% and 30% of sympathetic ophthalmia cases, respectively. Historically considered exacerbated by infectious agents, current understanding confirms that\u00a0the condition predominantly arises without intraocular infection."}
{"id": "article-151525_22", "title": "Sympathetic Ophthalmia -- Pathophysiology -- The Mechanism of Pathology", "content": "Research conducted by Marak and subsequent studies by Wong et al have elucidated that patients exhibit lymphocytes that react to specific uveal-retinal antigens. These findings underscore the pivotal role of genetic predispositions in the etiopathogenesis of sympathetic ophthalmia. Notably, associations have been identified with specific HLA haplotypes, namely HLA-A11, HLA-B40, HLA-DR4/DRw53, and HLA-DR4/DQw3. Moreover, a notable correlation has been established between HLA-DRB14 and HLA-DQB104 alleles and the susceptibility to sympathetic ophthalmia. [44]", "contents": "Sympathetic Ophthalmia -- Pathophysiology -- The Mechanism of Pathology. Research conducted by Marak and subsequent studies by Wong et al have elucidated that patients exhibit lymphocytes that react to specific uveal-retinal antigens. These findings underscore the pivotal role of genetic predispositions in the etiopathogenesis of sympathetic ophthalmia. Notably, associations have been identified with specific HLA haplotypes, namely HLA-A11, HLA-B40, HLA-DR4/DRw53, and HLA-DR4/DQw3. Moreover, a notable correlation has been established between HLA-DRB14 and HLA-DQB104 alleles and the susceptibility to sympathetic ophthalmia. [44]"}
{"id": "article-151525_23", "title": "Sympathetic Ophthalmia -- Pathophysiology -- The Mechanism of Pathology", "content": "The pathophysiological mechanism underlying\u00a0sympathetic ophthalmia\u00a0is hypothesized to initiate with an iatrogenic or traumatic event that triggers the afferent arm of an autoimmune response, possibly due to the unveiling of hidden ocular antigens to the immune system or a disruption in immune tolerance to these antigens. [45] Despite the absence of a traditional lymphatic system in the eye, antigen-presenting cells (APCs), predominantly macrophages or dendritic cells, process the ocular antigen and present\u00a0the peptides to autoreactive CD4+ T cells, specifically Th1 cells, via HLA class II molecules within the lymph nodes or spleen. The interaction of the antigen peptide with the T cell receptor results in Th1 cell activation and proliferation. These autoreactive cells traverse to the ocular tissues, where a confluence of altered endothelial integrity, a shift in cytokine profiles, and the activation of several effector pathways culminate in damage to the sympathizing eye. [46]", "contents": "Sympathetic Ophthalmia -- Pathophysiology -- The Mechanism of Pathology. The pathophysiological mechanism underlying\u00a0sympathetic ophthalmia\u00a0is hypothesized to initiate with an iatrogenic or traumatic event that triggers the afferent arm of an autoimmune response, possibly due to the unveiling of hidden ocular antigens to the immune system or a disruption in immune tolerance to these antigens. [45] Despite the absence of a traditional lymphatic system in the eye, antigen-presenting cells (APCs), predominantly macrophages or dendritic cells, process the ocular antigen and present\u00a0the peptides to autoreactive CD4+ T cells, specifically Th1 cells, via HLA class II molecules within the lymph nodes or spleen. The interaction of the antigen peptide with the T cell receptor results in Th1 cell activation and proliferation. These autoreactive cells traverse to the ocular tissues, where a confluence of altered endothelial integrity, a shift in cytokine profiles, and the activation of several effector pathways culminate in damage to the sympathizing eye. [46]"}
{"id": "article-151525_24", "title": "Sympathetic Ophthalmia -- Pathophysiology -- Immunological Cascade", "content": "A widespread granulomatous inflammation within the uveal tract defines the immunopathological profile of sympathetic ophthalmia. This reaction comprises an aggregation of lymphocytes, plasma cells, and clusters of epithelioid histiocytes. Notably, pigmentation is often identified within these epithelioid cells and giant cells. A distinctive characteristic is that the inflammation does not extend to involve the choriocapillaris or the retina in histopathological specimens. [4]", "contents": "Sympathetic Ophthalmia -- Pathophysiology -- Immunological Cascade. A widespread granulomatous inflammation within the uveal tract defines the immunopathological profile of sympathetic ophthalmia. This reaction comprises an aggregation of lymphocytes, plasma cells, and clusters of epithelioid histiocytes. Notably, pigmentation is often identified within these epithelioid cells and giant cells. A distinctive characteristic is that the inflammation does not extend to involve the choriocapillaris or the retina in histopathological specimens. [4]"}
{"id": "article-151525_25", "title": "Sympathetic Ophthalmia -- Pathophysiology -- Immunological Cascade", "content": "The choroid remains the primary focus of inflammatory activity, while retinal involvement is typically minimal. Clinically, Dalen\u2013Fuchs nodules present as yellow-white lesions within the peripheral retina, which can progress toward the optic disc and potentially affect the posterior pole. The frequency of\u00a0Dalen-Fuchs nodules in cases of sympathetic ophthalmia ranges from 25% to 35%. However, this incidence rises to 41.5% when a single peripheral nodule is considered indicative of the disease. [3] These nodules exhibit various morphologies: some display focal hyperplasia of the retinal pigment epithelium, while others show intact retinal pigment epithelium overlying lymphocytes and epithelioid cells. In more advanced stages,\u00a0the degeneration and disorganization of the nodules can occur, leading to the subretinal discharge of the nodular contents. [47]", "contents": "Sympathetic Ophthalmia -- Pathophysiology -- Immunological Cascade. The choroid remains the primary focus of inflammatory activity, while retinal involvement is typically minimal. Clinically, Dalen\u2013Fuchs nodules present as yellow-white lesions within the peripheral retina, which can progress toward the optic disc and potentially affect the posterior pole. The frequency of\u00a0Dalen-Fuchs nodules in cases of sympathetic ophthalmia ranges from 25% to 35%. However, this incidence rises to 41.5% when a single peripheral nodule is considered indicative of the disease. [3] These nodules exhibit various morphologies: some display focal hyperplasia of the retinal pigment epithelium, while others show intact retinal pigment epithelium overlying lymphocytes and epithelioid cells. In more advanced stages,\u00a0the degeneration and disorganization of the nodules can occur, leading to the subretinal discharge of the nodular contents. [47]"}
{"id": "article-151525_26", "title": "Sympathetic Ophthalmia -- Pathophysiology -- Immunological Cascade", "content": "Initially, the physical mass of nodules results in an apparent elevation of the overlying retinal structures, which, over time, gives way to atrophic changes. These nodules consist of nodular accumulations of pigmented epithelioid cells between the retinal pigment epithelium and Bruch membrane. Under microscopic examination, these cells reveal a distinctive ultrastructure featuring prominent organelles consistent with an active metabolic state. Autofluorescence studies reveal these cells as innumerable yellowish-orange specks corresponding to lipofuscin, reinforcing the theory that transformed cells constitute the primary cellular component of\u00a0Dalen-Fuchs nodules. [48]", "contents": "Sympathetic Ophthalmia -- Pathophysiology -- Immunological Cascade. Initially, the physical mass of nodules results in an apparent elevation of the overlying retinal structures, which, over time, gives way to atrophic changes. These nodules consist of nodular accumulations of pigmented epithelioid cells between the retinal pigment epithelium and Bruch membrane. Under microscopic examination, these cells reveal a distinctive ultrastructure featuring prominent organelles consistent with an active metabolic state. Autofluorescence studies reveal these cells as innumerable yellowish-orange specks corresponding to lipofuscin, reinforcing the theory that transformed cells constitute the primary cellular component of\u00a0Dalen-Fuchs nodules. [48]"}
{"id": "article-151525_27", "title": "Sympathetic Ophthalmia -- Pathophysiology -- Immunological Cascade", "content": "When\u00a0the retina typically remains unscathed, mononuclear cellular aggregates around blood vessels and over Dalen-Fuchs nodules have been observed in enucleated specimens. The sclera may also be implicated along emissary veins, and inflammatory exudates have been noted to extend to the optic nerve and meninges. Atypical histopathological features, such as phaco anaphylactic reactions to the disrupted lens material characterized by zonal granulomatous inflammation, have been documented. [49]", "contents": "Sympathetic Ophthalmia -- Pathophysiology -- Immunological Cascade. When\u00a0the retina typically remains unscathed, mononuclear cellular aggregates around blood vessels and over Dalen-Fuchs nodules have been observed in enucleated specimens. The sclera may also be implicated along emissary veins, and inflammatory exudates have been noted to extend to the optic nerve and meninges. Atypical histopathological features, such as phaco anaphylactic reactions to the disrupted lens material characterized by zonal granulomatous inflammation, have been documented. [49]"}
{"id": "article-151525_28", "title": "Sympathetic Ophthalmia -- Pathophysiology -- Immunological Cascade", "content": "Immunohistochemical analyses have identified a predominance of T lymphocyte infiltration within the uveal tract, with B lymphocyte presence in more protracted cases or those managed with corticosteroids. The early stages of the disease are characterized by a Th1 response, marked by an abundance of CD4+ T cells and the secretion of proinflammatory cytokines. In contrast, CD8+ T cells are more common in chronic presentations of sympathetic ophthalmia. [50] Emerging research implicates TNF-\u03b1-induced oxidative stress within the outer retina as a potential early event precipitating photoreceptor apoptosis and subsequent vision impairment in sympathetic ophthalmia. Conversely, protective molecular markers, such as \u03b1-A-crystallin, have been detected in the outer retinal layers. The increased expression of Fas and FasL in afflicted eyes hints at apoptosis playing a regulatory role in mitigating ocular inflammation. [51]", "contents": "Sympathetic Ophthalmia -- Pathophysiology -- Immunological Cascade. Immunohistochemical analyses have identified a predominance of T lymphocyte infiltration within the uveal tract, with B lymphocyte presence in more protracted cases or those managed with corticosteroids. The early stages of the disease are characterized by a Th1 response, marked by an abundance of CD4+ T cells and the secretion of proinflammatory cytokines. In contrast, CD8+ T cells are more common in chronic presentations of sympathetic ophthalmia. [50] Emerging research implicates TNF-\u03b1-induced oxidative stress within the outer retina as a potential early event precipitating photoreceptor apoptosis and subsequent vision impairment in sympathetic ophthalmia. Conversely, protective molecular markers, such as \u03b1-A-crystallin, have been detected in the outer retinal layers. The increased expression of Fas and FasL in afflicted eyes hints at apoptosis playing a regulatory role in mitigating ocular inflammation. [51]"}
{"id": "article-151525_29", "title": "Sympathetic Ophthalmia -- Pathophysiology -- Immunological Cascade", "content": "Interleukin-23 or interleukin-17 signaling has been implicated in autoinflammatory and autoimmune uveitis pathogenesis akin to sympathetic ophthalmia, influencing cell function and exacerbating intraocular inflammation. Targeting this pathway may represent a novel therapeutic approach. Additionally, altered expression of specific microRNAs has been associated with increased proinflammatory cytokine activity, particularly TNF-\u03b1, and NF-\u03baB, underscoring their importance in the pathogenesis. [52]", "contents": "Sympathetic Ophthalmia -- Pathophysiology -- Immunological Cascade. Interleukin-23 or interleukin-17 signaling has been implicated in autoinflammatory and autoimmune uveitis pathogenesis akin to sympathetic ophthalmia, influencing cell function and exacerbating intraocular inflammation. Targeting this pathway may represent a novel therapeutic approach. Additionally, altered expression of specific microRNAs has been associated with increased proinflammatory cytokine activity, particularly TNF-\u03b1, and NF-\u03baB, underscoring their importance in the pathogenesis. [52]"}
{"id": "article-151525_30", "title": "Sympathetic Ophthalmia -- Histopathology", "content": "The histopathology of sympathetic ophthalmia classically shows widespread bilateral uveal inflammation characterized by lymphocytes surrounding non-necrotizing granulomas composed of multinucleated giant cells and macrophages. [53] Notably, similar changes\u00a0are found\u00a0in the inciting and the sympathizing eye. Immunohistochemical studies demonstrate lymphocytic granulomatous uveal inflammation\u00a0where CD4+ T helper cells predominate during the early stages of the disease, followed by CD8+ T suppressor cells during later stages. More recent studies also unveiled B cells as potential contributors to the inflammatory process toward end-stage disease. [34] [54]", "contents": "Sympathetic Ophthalmia -- Histopathology. The histopathology of sympathetic ophthalmia classically shows widespread bilateral uveal inflammation characterized by lymphocytes surrounding non-necrotizing granulomas composed of multinucleated giant cells and macrophages. [53] Notably, similar changes\u00a0are found\u00a0in the inciting and the sympathizing eye. Immunohistochemical studies demonstrate lymphocytic granulomatous uveal inflammation\u00a0where CD4+ T helper cells predominate during the early stages of the disease, followed by CD8+ T suppressor cells during later stages. More recent studies also unveiled B cells as potential contributors to the inflammatory process toward end-stage disease. [34] [54]"}
{"id": "article-151525_31", "title": "Sympathetic Ophthalmia -- Histopathology", "content": "TNF-\u03b1, an inflammatory cytokine, may mediate oxidative stress in the outer retina during sympathetic ophthalmia, resulting in photoreceptor apoptosis and vision loss. [55] Interleukin-23 and interleukin-17\u00a0may also target\u00a0retinal pigment epithelial cells in this disease. Classically, inflammation from sympathetic ophthalmia spares the choriocapillaris, though some recent studies have\u00a0documented cases where the choriocapillaris can be involved. [56] [57]", "contents": "Sympathetic Ophthalmia -- Histopathology. TNF-\u03b1, an inflammatory cytokine, may mediate oxidative stress in the outer retina during sympathetic ophthalmia, resulting in photoreceptor apoptosis and vision loss. [55] Interleukin-23 and interleukin-17\u00a0may also target\u00a0retinal pigment epithelial cells in this disease. Classically, inflammation from sympathetic ophthalmia spares the choriocapillaris, though some recent studies have\u00a0documented cases where the choriocapillaris can be involved. [56] [57]"}
{"id": "article-151525_32", "title": "Sympathetic Ophthalmia -- Histopathology", "content": "Dalen-Fuchs nodules are lesions of the retinal pigment epithelium characteristically associated with sympathetic ophthalmia. Still, they are only seen in 25% to 35% of cases and are not pathognomonic to the disease. [58] Dalen\u2013Fuchs nodules are present in an estimated 30% of patients. These microscopic structures comprise lymphocytes, histiocytes, and altered retinal pigment epithelial cells beneath the Bruch membrane.\u00a0Morphological diversity in these nodules\u00a0occurs. Descriptions outline\u00a03\u00a0distinct types of lesions: the first involves localized proliferation and clustering of retinal pigment epithelial\u00a0cells, the second is the traditional Dalen\u2013Fuchs nodule, where a continuous layer caps epithelioid cells and lymphocytes, and the third\u00a0is characterized\u00a0by degenerative changes, leading to disorganized nodules and potential dispersion into the subretinal region. [3] Three different morphologies of these lesions follow:", "contents": "Sympathetic Ophthalmia -- Histopathology. Dalen-Fuchs nodules are lesions of the retinal pigment epithelium characteristically associated with sympathetic ophthalmia. Still, they are only seen in 25% to 35% of cases and are not pathognomonic to the disease. [58] Dalen\u2013Fuchs nodules are present in an estimated 30% of patients. These microscopic structures comprise lymphocytes, histiocytes, and altered retinal pigment epithelial cells beneath the Bruch membrane.\u00a0Morphological diversity in these nodules\u00a0occurs. Descriptions outline\u00a03\u00a0distinct types of lesions: the first involves localized proliferation and clustering of retinal pigment epithelial\u00a0cells, the second is the traditional Dalen\u2013Fuchs nodule, where a continuous layer caps epithelioid cells and lymphocytes, and the third\u00a0is characterized\u00a0by degenerative changes, leading to disorganized nodules and potential dispersion into the subretinal region. [3] Three different morphologies of these lesions follow:"}
{"id": "article-151525_33", "title": "Sympathetic Ophthalmia -- Histopathology", "content": "Focal\u00a0retinal pigment epithelial\u00a0hyperplasia and aggregation Classic Dalen-Fuchs nodules, described as lymphocytes and epithelioid cells that exist between retinal pigment epithelial and Bruch membrane Nodules with disruption of the overlying retinal pigment epithelial resulting in potential eruption into the subretinal space [59]", "contents": "Sympathetic Ophthalmia -- Histopathology. Focal\u00a0retinal pigment epithelial\u00a0hyperplasia and aggregation Classic Dalen-Fuchs nodules, described as lymphocytes and epithelioid cells that exist between retinal pigment epithelial and Bruch membrane Nodules with disruption of the overlying retinal pigment epithelial resulting in potential eruption into the subretinal space [59]"}
{"id": "article-151525_34", "title": "Sympathetic Ophthalmia -- Histopathology", "content": "No\u00a0known correlation exists between the extent of histopathological findings and the final visual outcome\u00a0in sympathetic ophthalmia. [56] Sympathetic ophthalmia is a comprehensive inflammatory eye disease that manifests as panuveitis. Upon histological examination, the disease exhibits a pervasive thickening throughout the uveal tract, including the choroid, ciliary body, and iris. Notably, the inflammatory alterations are comparable in both the triggering and the affected eye. Though the proportions vary, the inflammatory response predominantly comprises lymphocytes, epithelioid cells, and multinucleated giant cells. Traditionally,\u00a0the condition is understood to spare the choriocapillaris; however, research by Rathinam\u00a0et al\u00a0uncovered instances of lymphocytic infiltration within the choriocapillaris in select regions, alongside focal necrosis in cases where\u00a0sympathetic ophthalmia\u00a0is concurrent with endophthalmitis. [60]", "contents": "Sympathetic Ophthalmia -- Histopathology. No\u00a0known correlation exists between the extent of histopathological findings and the final visual outcome\u00a0in sympathetic ophthalmia. [56] Sympathetic ophthalmia is a comprehensive inflammatory eye disease that manifests as panuveitis. Upon histological examination, the disease exhibits a pervasive thickening throughout the uveal tract, including the choroid, ciliary body, and iris. Notably, the inflammatory alterations are comparable in both the triggering and the affected eye. Though the proportions vary, the inflammatory response predominantly comprises lymphocytes, epithelioid cells, and multinucleated giant cells. Traditionally,\u00a0the condition is understood to spare the choriocapillaris; however, research by Rathinam\u00a0et al\u00a0uncovered instances of lymphocytic infiltration within the choriocapillaris in select regions, alongside focal necrosis in cases where\u00a0sympathetic ophthalmia\u00a0is concurrent with endophthalmitis. [60]"}
{"id": "article-151525_35", "title": "Sympathetic Ophthalmia -- Histopathology", "content": "Immunopathologically, the condition is marked by an initial surge of CD4+ helper or inducer T cells, with a subsequent rise in CD8+ suppressor or cytotoxic T cells, illustrating an active and changing T cell-mediated immune response during\u00a0the progression. Additionally, B cells within the uveal infiltrate have\u00a0been observed, contrasting with the previously believed T cell dominance and suggesting the potential role of B cell-mediated activation of autoreactive T cells as the disease progresses.\u00a0Evidence suggests\u00a0genetic factors may contribute to the susceptibility to sympathetic ophthalmia, particularly alleles in the human leukocyte antigen system, such as HLA-A11, Cw, DRB104, DQB104, DR4, as well as the related DQw3 and DRw53. [61]", "contents": "Sympathetic Ophthalmia -- Histopathology. Immunopathologically, the condition is marked by an initial surge of CD4+ helper or inducer T cells, with a subsequent rise in CD8+ suppressor or cytotoxic T cells, illustrating an active and changing T cell-mediated immune response during\u00a0the progression. Additionally, B cells within the uveal infiltrate have\u00a0been observed, contrasting with the previously believed T cell dominance and suggesting the potential role of B cell-mediated activation of autoreactive T cells as the disease progresses.\u00a0Evidence suggests\u00a0genetic factors may contribute to the susceptibility to sympathetic ophthalmia, particularly alleles in the human leukocyte antigen system, such as HLA-A11, Cw, DRB104, DQB104, DR4, as well as the related DQw3 and DRw53. [61]"}
{"id": "article-151525_36", "title": "Sympathetic Ophthalmia -- History and Physical", "content": "The timeline for the onset of sympathetic ophthalmia can range from days to years after the initial injury to the inciting eye; however, 90% of cases occur within\u00a01\u00a0year. [31] Patients with sympathetic ophthalmia may have significant variability\u00a0in their initial presentation. Unfortunately, patients may experience recurrent episodes despite resolution after the initial episode. Upon seeing patients with bilateral uveitis, an accurate history\u00a0focuses on whether the patient has had a history of traumatic ocular injury or prior eye surgeries. Early-stage sympathetic ophthalmia may present with isolated mild anterior segment inflammation or isolated posterior segment inflammation. Detection during this early stage may lead to a better visual prognosis with\u00a0prompt treatment. [30]", "contents": "Sympathetic Ophthalmia -- History and Physical. The timeline for the onset of sympathetic ophthalmia can range from days to years after the initial injury to the inciting eye; however, 90% of cases occur within\u00a01\u00a0year. [31] Patients with sympathetic ophthalmia may have significant variability\u00a0in their initial presentation. Unfortunately, patients may experience recurrent episodes despite resolution after the initial episode. Upon seeing patients with bilateral uveitis, an accurate history\u00a0focuses on whether the patient has had a history of traumatic ocular injury or prior eye surgeries. Early-stage sympathetic ophthalmia may present with isolated mild anterior segment inflammation or isolated posterior segment inflammation. Detection during this early stage may lead to a better visual prognosis with\u00a0prompt treatment. [30]"}
{"id": "article-151525_37", "title": "Sympathetic Ophthalmia -- History and Physical", "content": "Symptoms may range from mild visual disturbances to significant vision loss. Other symptoms include pain, photophobia, epiphora, floaters, and redness. [26] [62] Due to inflammation of the ciliary body affecting accommodation, near vision may be affected during the early stages of sympathetic ophthalmia. Most patients have asymmetric bilateral uveitis, displaying more significant inflammation in the inciting eye.", "contents": "Sympathetic Ophthalmia -- History and Physical. Symptoms may range from mild visual disturbances to significant vision loss. Other symptoms include pain, photophobia, epiphora, floaters, and redness. [26] [62] Due to inflammation of the ciliary body affecting accommodation, near vision may be affected during the early stages of sympathetic ophthalmia. Most patients have asymmetric bilateral uveitis, displaying more significant inflammation in the inciting eye."}
{"id": "article-151525_38", "title": "Sympathetic Ophthalmia -- History and Physical", "content": "Anterior segment findings may range from mild bilateral anterior segment inflammation to bilateral granulomatous inflammation with mutton-fat corneal precipitates. Posterior iris synechiae and peripheral anterior synechiae may be present. Iris thickening with or without iris nodules\u00a0is seen. Intraocular pressure\u00a0is low in the setting of ciliary body shutdown or high secondary to trabeculitis or obstruction of the trabecular meshwork.", "contents": "Sympathetic Ophthalmia -- History and Physical. Anterior segment findings may range from mild bilateral anterior segment inflammation to bilateral granulomatous inflammation with mutton-fat corneal precipitates. Posterior iris synechiae and peripheral anterior synechiae may be present. Iris thickening with or without iris nodules\u00a0is seen. Intraocular pressure\u00a0is low in the setting of ciliary body shutdown or high secondary to trabeculitis or obstruction of the trabecular meshwork."}
{"id": "article-151525_39", "title": "Sympathetic Ophthalmia -- History and Physical", "content": "Examination of the posterior segment in cases of sympathetic ophthalmia commonly reveals a spectrum of inflammatory manifestations, including vitreous haze and opacities, inflammation of the optic nerve head, inflammation of the retinal blood vessels, serous retinal separation, and inflammation of the vascular layer beneath the retina. The initial indicators often involve subtle inflammation in the front of the eye, minimal cells behind the lens, and optic disc redness. The severity of the inflammatory response can range from minor, with several small, isolated serous detachments near the optic nerve and macula, to extensive serous retinal separation. These presentations may include discreet yellowish-white spots at the choroidal level in the early stages, commonly identified as Dalen\u2013Fuchs nodules.\u00a0They are typically observed around the eye\u2019s equator and peripheral regions. [63]", "contents": "Sympathetic Ophthalmia -- History and Physical. Examination of the posterior segment in cases of sympathetic ophthalmia commonly reveals a spectrum of inflammatory manifestations, including vitreous haze and opacities, inflammation of the optic nerve head, inflammation of the retinal blood vessels, serous retinal separation, and inflammation of the vascular layer beneath the retina. The initial indicators often involve subtle inflammation in the front of the eye, minimal cells behind the lens, and optic disc redness. The severity of the inflammatory response can range from minor, with several small, isolated serous detachments near the optic nerve and macula, to extensive serous retinal separation. These presentations may include discreet yellowish-white spots at the choroidal level in the early stages, commonly identified as Dalen\u2013Fuchs nodules.\u00a0They are typically observed around the eye\u2019s equator and peripheral regions. [63]"}
{"id": "article-151525_40", "title": "Sympathetic Ophthalmia -- History and Physical", "content": "Over time, these nodules are prone to degenerative changes, leading to thinning and atrophy. The pattern and magnitude of the fluid accumulation beneath the retina\u00a0are\u00a0quite\u00a0variable, sometimes presenting as localized detachments in the region adjacent to the optic disc across the central retinal area or as a more extensive detachment scenario. Though indicative of the underlying inflammatory process, these nodules are often a marker of disease progression and the body\u2019s response to the condition. Posterior segment exam findings may include mild to severe vitritis, Dalen-Fuch nodules (yellow-white lesions of the retinal pigment epithelium), choroiditis, papillitis, and retinal vasculitis. Exudative retinal detachment may vary from small pockets of peripapillary exudative detachments to more extensive serous retinal detachments. [3] [26]", "contents": "Sympathetic Ophthalmia -- History and Physical. Over time, these nodules are prone to degenerative changes, leading to thinning and atrophy. The pattern and magnitude of the fluid accumulation beneath the retina\u00a0are\u00a0quite\u00a0variable, sometimes presenting as localized detachments in the region adjacent to the optic disc across the central retinal area or as a more extensive detachment scenario. Though indicative of the underlying inflammatory process, these nodules are often a marker of disease progression and the body\u2019s response to the condition. Posterior segment exam findings may include mild to severe vitritis, Dalen-Fuch nodules (yellow-white lesions of the retinal pigment epithelium), choroiditis, papillitis, and retinal vasculitis. Exudative retinal detachment may vary from small pockets of peripapillary exudative detachments to more extensive serous retinal detachments. [3] [26]"}
{"id": "article-151525_41", "title": "Sympathetic Ophthalmia -- History and Physical", "content": "Chronic sympathetic ophthalmia may also cause subretinal fibrosis and choroidal neovascularization. [4] A late-stage finding of sympathetic ophthalmia is the\u00a0\u201csunset glow fundus,\u201d where the retina has a red-orange appearance due to depigmentation of the inflamed choroid and retinal pigment epithelium. [64] The\u00a0\u201csunset glow\u201d fundus, a hallmark characteristic often observed in the advanced stages of sympathetic ophthalmia, emerges due to pigmentary depletion within the choroidal layer and alterations in the retinal pigment epithelium. Recurrent inflammation in the front part of the eye, accompanied by this\u00a0\u201csunset glow\u201d appearance, is a notable clinical manifestation of sympathetic ophthalmia. The range of post-inflammatory sequelae varies widely and\u00a0is influenced\u00a0by the intensity of the inflammation and the timeliness and effectiveness of the treatment.", "contents": "Sympathetic Ophthalmia -- History and Physical. Chronic sympathetic ophthalmia may also cause subretinal fibrosis and choroidal neovascularization. [4] A late-stage finding of sympathetic ophthalmia is the\u00a0\u201csunset glow fundus,\u201d where the retina has a red-orange appearance due to depigmentation of the inflamed choroid and retinal pigment epithelium. [64] The\u00a0\u201csunset glow\u201d fundus, a hallmark characteristic often observed in the advanced stages of sympathetic ophthalmia, emerges due to pigmentary depletion within the choroidal layer and alterations in the retinal pigment epithelium. Recurrent inflammation in the front part of the eye, accompanied by this\u00a0\u201csunset glow\u201d appearance, is a notable clinical manifestation of sympathetic ophthalmia. The range of post-inflammatory sequelae varies widely and\u00a0is influenced\u00a0by the intensity of the inflammation and the timeliness and effectiveness of the treatment."}
{"id": "article-151525_42", "title": "Sympathetic Ophthalmia -- History and Physical", "content": "Complications such as secondary glaucoma and cataract formation are frequently encountered, either as direct consequences of the disease or as adverse effects of corticosteroid therapy. Additionally, atrophy of the retina and optic nerve can develop as a sequel to persistent retinal separation, subretinal scarring, and attendant atrophic changes in the choroid. Although less common, the development of choroidal neovascularization and phthisis\u00a0bulbi\u00a0are serious complications that typically indicate a history of delayed diagnosis or suboptimal management. [65]", "contents": "Sympathetic Ophthalmia -- History and Physical. Complications such as secondary glaucoma and cataract formation are frequently encountered, either as direct consequences of the disease or as adverse effects of corticosteroid therapy. Additionally, atrophy of the retina and optic nerve can develop as a sequel to persistent retinal separation, subretinal scarring, and attendant atrophic changes in the choroid. Although less common, the development of choroidal neovascularization and phthisis\u00a0bulbi\u00a0are serious complications that typically indicate a history of delayed diagnosis or suboptimal management. [65]"}
{"id": "article-151525_43", "title": "Sympathetic Ophthalmia -- Evaluation", "content": "Essential for diagnosing sympathetic ophthalmia\u00a0are the characteristic findings of bilateral uveitis following an event of trauma or surgical intervention to\u00a01 eye. This condition presents with inflammation across multiple eye segments involving the anterior chamber, vitreous body, and choroid. While the diagnosis primarily rests on clinical grounds, a suite of imaging techniques is pivotal for confirming and tracking treatment efficacy and disease course. These supplemental diagnostic measures are instrumental for clinicians in comprehensively managing sympathetic ophthalmia. The SUN working group criteria for sympathetic ophthalmia diagnosis is a patient with a history of unilateral ocular trauma or surgery with ocular inflammation in both eyes and either anterior uveitis with vitreous inflammation or panuveitis with choroidal involvement. [1] Though sympathetic ophthalmia\u00a0remains a clinical diagnosis, multiple imaging modalities\u00a0can\u00a0assist ophthalmologists in confirming the diagnosis, tracking disease progression, and monitoring response to treatment.", "contents": "Sympathetic Ophthalmia -- Evaluation. Essential for diagnosing sympathetic ophthalmia\u00a0are the characteristic findings of bilateral uveitis following an event of trauma or surgical intervention to\u00a01 eye. This condition presents with inflammation across multiple eye segments involving the anterior chamber, vitreous body, and choroid. While the diagnosis primarily rests on clinical grounds, a suite of imaging techniques is pivotal for confirming and tracking treatment efficacy and disease course. These supplemental diagnostic measures are instrumental for clinicians in comprehensively managing sympathetic ophthalmia. The SUN working group criteria for sympathetic ophthalmia diagnosis is a patient with a history of unilateral ocular trauma or surgery with ocular inflammation in both eyes and either anterior uveitis with vitreous inflammation or panuveitis with choroidal involvement. [1] Though sympathetic ophthalmia\u00a0remains a clinical diagnosis, multiple imaging modalities\u00a0can\u00a0assist ophthalmologists in confirming the diagnosis, tracking disease progression, and monitoring response to treatment."}
{"id": "article-151525_44", "title": "Sympathetic Ophthalmia -- Evaluation -- B-Scan Ultrasonography", "content": "B-scan ultrasonography may reveal diffuse choroidal thickening and serous retinal detachments. B-scan is particularly valuable in the case of dense vitritis, posterior synechiae, corneal opacity, or any other pathology\u00a0that prevents\u00a0a clear view\u00a0of the retina. [4] [66] Enhanced-depth imaging optical coherence tomography (EDI-OCT) is the preferred method for assessing choroidal thickness. Research indicates that individuals with sympathetic ophthalmia often exhibit widespread choroidal swelling and a mild serous retina detachment, particularly in the macular region.", "contents": "Sympathetic Ophthalmia -- Evaluation -- B-Scan Ultrasonography. B-scan ultrasonography may reveal diffuse choroidal thickening and serous retinal detachments. B-scan is particularly valuable in the case of dense vitritis, posterior synechiae, corneal opacity, or any other pathology\u00a0that prevents\u00a0a clear view\u00a0of the retina. [4] [66] Enhanced-depth imaging optical coherence tomography (EDI-OCT) is the preferred method for assessing choroidal thickness. Research indicates that individuals with sympathetic ophthalmia often exhibit widespread choroidal swelling and a mild serous retina detachment, particularly in the macular region."}
{"id": "article-151525_45", "title": "Sympathetic Ophthalmia -- Evaluation -- Fundus Autofluorescence", "content": "The imaging\u00a0detects lipofuscin in the retinal pigment epithelium, enabling visualization of dysfunction and death. This simple, noninvasive test is\u00a0useful\u00a0in assessing sympathetic ophthalmia,\u00a0showing the extent of damage caused by inflammation and helping identify potential sequelae like choroidal neovascularization. In acute disease, a petaloid pattern of hyper-autofluorescence centered on the optic nerve may be present in areas of serous retinal detachments. [67] With the resolution of the subretinal fluid, fundus autofluorescence (FAF)\u00a0may display leopard spots with mixed areas of hyper- and hypo-autofluorescence. [68]", "contents": "Sympathetic Ophthalmia -- Evaluation -- Fundus Autofluorescence. The imaging\u00a0detects lipofuscin in the retinal pigment epithelium, enabling visualization of dysfunction and death. This simple, noninvasive test is\u00a0useful\u00a0in assessing sympathetic ophthalmia,\u00a0showing the extent of damage caused by inflammation and helping identify potential sequelae like choroidal neovascularization. In acute disease, a petaloid pattern of hyper-autofluorescence centered on the optic nerve may be present in areas of serous retinal detachments. [67] With the resolution of the subretinal fluid, fundus autofluorescence (FAF)\u00a0may display leopard spots with mixed areas of hyper- and hypo-autofluorescence. [68]"}
{"id": "article-151525_46", "title": "Sympathetic Ophthalmia -- Evaluation -- Fundus Autofluorescence", "content": "FAF in chronic sympathetic ophthalmia\u00a0has a varied presentation depending on the sequelae of the disease, as previously described. Decreased autofluorescence may be detected secondary to outer retinal damage,\u00a0retinal pigment epithelial loss, nummular scars, and peripapillary atrophy. Increased autofluorescence may\u00a0be seen\u00a0in\u00a0cystic macular edema, subretinal fibrosis, and proliferation. [69] During active phases of the disease, enhanced autofluorescence imaging reveals intensified signals that align with areas where the neurosensory retina has detached. As the disease resolves, leading to alterations in the retinal pigment epithelium, the autofluorescence patterns evolve, displaying a speckled increase in autofluorescence that resembles leopard spotting. Autofluorescence imaging is\u00a0useful\u00a0to assess the condition, where increased autofluorescence signifies a metabolically active epithelium, and decreased signals indicate loss. Nevertheless, since sympathetic ophthalmia primarily affects the choroidal stroma, imaging does not\u00a0facilitate\u00a0diagnosing or managing the condition. [70]", "contents": "Sympathetic Ophthalmia -- Evaluation -- Fundus Autofluorescence. FAF in chronic sympathetic ophthalmia\u00a0has a varied presentation depending on the sequelae of the disease, as previously described. Decreased autofluorescence may be detected secondary to outer retinal damage,\u00a0retinal pigment epithelial loss, nummular scars, and peripapillary atrophy. Increased autofluorescence may\u00a0be seen\u00a0in\u00a0cystic macular edema, subretinal fibrosis, and proliferation. [69] During active phases of the disease, enhanced autofluorescence imaging reveals intensified signals that align with areas where the neurosensory retina has detached. As the disease resolves, leading to alterations in the retinal pigment epithelium, the autofluorescence patterns evolve, displaying a speckled increase in autofluorescence that resembles leopard spotting. Autofluorescence imaging is\u00a0useful\u00a0to assess the condition, where increased autofluorescence signifies a metabolically active epithelium, and decreased signals indicate loss. Nevertheless, since sympathetic ophthalmia primarily affects the choroidal stroma, imaging does not\u00a0facilitate\u00a0diagnosing or managing the condition. [70]"}
{"id": "article-151525_47", "title": "Sympathetic Ophthalmia -- Evaluation -- Optical Coherence Tomography", "content": "The introduction of enhanced depth imaging OCT (EDI-OCT) and swept-source OCT technologies has revolutionized the visualization of retinal and choroidal structures, producing high-definition images spectral-domain optical coherence tomography (SD-OCT) with or without enhanced depth imaging (EDI-OCT) and swept-source OCT (SS-OCT) are noninvasive imaging modalities that allow for high-resolution examination of the retina and choroid. [71]", "contents": "Sympathetic Ophthalmia -- Evaluation -- Optical Coherence Tomography. The introduction of enhanced depth imaging OCT (EDI-OCT) and swept-source OCT technologies has revolutionized the visualization of retinal and choroidal structures, producing high-definition images spectral-domain optical coherence tomography (SD-OCT) with or without enhanced depth imaging (EDI-OCT) and swept-source OCT (SS-OCT) are noninvasive imaging modalities that allow for high-resolution examination of the retina and choroid. [71]"}
{"id": "article-151525_48", "title": "Sympathetic Ophthalmia -- Evaluation -- Optical Coherence Tomography", "content": "Sympathetic ophthalmia may initially present with serous retinal detachments seen on swept-source OCT.\u00a0The detachments\u00a0contain hyperreflective septa, representing bacillary layer detachment splitting the photoreceptor layer at the inner segment myoid. Of note is that this finding is also seen in Vogt-Kayanagi-Harada (VKH) disease and resolves rapidly with corticosteroid treatment. [72] Dalen-Fuchs nodules, classically seen in 25% to 35% of patients with sympathetic ophthalmia, initially appear as round hyperreflective areas in the outer retina with occasional serous detachments of the overlying neurosensory retina. These lesions\u00a0regress with therapy. [73] EDI-OCT and SS-OCT can also identify the presence of choroidal thickening, subretinal choroidal folds, and increased choroidal vascularity index. These findings typically resolve with treatment, though\u00a0useful\u00a0in monitoring treatment response. [74] [75]", "contents": "Sympathetic Ophthalmia -- Evaluation -- Optical Coherence Tomography. Sympathetic ophthalmia may initially present with serous retinal detachments seen on swept-source OCT.\u00a0The detachments\u00a0contain hyperreflective septa, representing bacillary layer detachment splitting the photoreceptor layer at the inner segment myoid. Of note is that this finding is also seen in Vogt-Kayanagi-Harada (VKH) disease and resolves rapidly with corticosteroid treatment. [72] Dalen-Fuchs nodules, classically seen in 25% to 35% of patients with sympathetic ophthalmia, initially appear as round hyperreflective areas in the outer retina with occasional serous detachments of the overlying neurosensory retina. These lesions\u00a0regress with therapy. [73] EDI-OCT and SS-OCT can also identify the presence of choroidal thickening, subretinal choroidal folds, and increased choroidal vascularity index. These findings typically resolve with treatment, though\u00a0useful\u00a0in monitoring treatment response. [74] [75]"}
{"id": "article-151525_49", "title": "Sympathetic Ophthalmia -- Evaluation -- Optical Coherence Tomography", "content": "Research conducted by Gupta and colleagues noted the repair of these OCT-detected abnormalities, including the continuity of the retinal pigment epithelium\u2013Bruch membrane complex and inner segment and outer segment of photoreceptor cells junction, following timely treatment in the acute phase of the disease. Furthermore, acute-phase alterations in the choroid are not limited to the outer retina but include extensive choroidal thickening, observable folds, and a loss of\u00a0normal\u00a0choroidal structure. Such choroidal thickening\u00a0is a significant OCT-based biomarker for tracking disease progression. The choroidal vascularity index (CVI), a novel OCT biomarker, has been introduced to monitor disease activity in cases of sympathetic ophthalmia. Notably, the CVI\u00a0is considered\u00a0a reliable metric, remaining constant and less susceptible to alteration by physiological variables.", "contents": "Sympathetic Ophthalmia -- Evaluation -- Optical Coherence Tomography. Research conducted by Gupta and colleagues noted the repair of these OCT-detected abnormalities, including the continuity of the retinal pigment epithelium\u2013Bruch membrane complex and inner segment and outer segment of photoreceptor cells junction, following timely treatment in the acute phase of the disease. Furthermore, acute-phase alterations in the choroid are not limited to the outer retina but include extensive choroidal thickening, observable folds, and a loss of\u00a0normal\u00a0choroidal structure. Such choroidal thickening\u00a0is a significant OCT-based biomarker for tracking disease progression. The choroidal vascularity index (CVI), a novel OCT biomarker, has been introduced to monitor disease activity in cases of sympathetic ophthalmia. Notably, the CVI\u00a0is considered\u00a0a reliable metric, remaining constant and less susceptible to alteration by physiological variables."}
{"id": "article-151525_50", "title": "Sympathetic Ophthalmia -- Evaluation -- Optical Coherence Tomography Angiography", "content": "This noninvasive imaging modality\u00a0is\u00a0designed\u00a0to examine the chorioretinal vasculature without intravenous dye. Optical coherence tomography angiography (OCTA) may demonstrate ischemia\u00a0and\u00a0reduced capillary density. [76] OCTA can also monitor\u00a0ischemic areas as patients respond to therapy. [4] [77] OCTA is also sensitive in detecting and differentiating choroidal neovascularization from inflammatory lesions\u00a0to tailor the patient\u2019s treatment plan. [78]", "contents": "Sympathetic Ophthalmia -- Evaluation -- Optical Coherence Tomography Angiography. This noninvasive imaging modality\u00a0is\u00a0designed\u00a0to examine the chorioretinal vasculature without intravenous dye. Optical coherence tomography angiography (OCTA) may demonstrate ischemia\u00a0and\u00a0reduced capillary density. [76] OCTA can also monitor\u00a0ischemic areas as patients respond to therapy. [4] [77] OCTA is also sensitive in detecting and differentiating choroidal neovascularization from inflammatory lesions\u00a0to tailor the patient\u2019s treatment plan. [78]"}
{"id": "article-151525_51", "title": "Sympathetic Ophthalmia -- Evaluation -- Optical Coherence Tomography Angiography", "content": "OCTA\u00a0has been pivotal in identifying small regions of compromised choriocapillaris perfusion, suggesting areas of ischemia within the choriocapillaris. These areas appear as flow voids on OCTA images, which typically diminish and resolve with appropriate treatment. OCTA has also enhanced the visualization of choroidal neovascular membranes, providing\u00a0clearer\u00a0images than other imaging modalities. [79]", "contents": "Sympathetic Ophthalmia -- Evaluation -- Optical Coherence Tomography Angiography. OCTA\u00a0has been pivotal in identifying small regions of compromised choriocapillaris perfusion, suggesting areas of ischemia within the choriocapillaris. These areas appear as flow voids on OCTA images, which typically diminish and resolve with appropriate treatment. OCTA has also enhanced the visualization of choroidal neovascular membranes, providing\u00a0clearer\u00a0images than other imaging modalities. [79]"}
{"id": "article-151525_52", "title": "Sympathetic Ophthalmia -- Evaluation -- Optical Coherence Tomography Angiography", "content": "In contrast to fluorescein angiography and indocyanine green angiography (ICGA), which yield 2-dimensional images, OCTA generates 3-dimensional visualizations based on volumetric data; this\u00a0provides\u00a0a more detailed analysis of the choriocapillaris and ischemic conditions, which often present as flow voids on OCTA and are analogous to the hypocyanescent lesions seen on indocyanine green angiography in inflammatory choroidal diseases such as Vogt-Koyanagi-Harada and sympathetic ophthalmia. [80]", "contents": "Sympathetic Ophthalmia -- Evaluation -- Optical Coherence Tomography Angiography. In contrast to fluorescein angiography and indocyanine green angiography (ICGA), which yield 2-dimensional images, OCTA generates 3-dimensional visualizations based on volumetric data; this\u00a0provides\u00a0a more detailed analysis of the choriocapillaris and ischemic conditions, which often present as flow voids on OCTA and are analogous to the hypocyanescent lesions seen on indocyanine green angiography in inflammatory choroidal diseases such as Vogt-Koyanagi-Harada and sympathetic ophthalmia. [80]"}
{"id": "article-151525_53", "title": "Sympathetic Ophthalmia -- Evaluation -- Optical Coherence Tomography Angiography", "content": "Despite\u00a0the advantages as a noninvasive imaging technique, especially for conditions affecting the choriocapillaris, OCTA has limitations in adequately capturing medium and\u00a0large\u00a0choroidal vessel details. Additionally, signal loss and artifacts can complicate the interpretation of flow voids, necessitating careful differentiation and occasionally leaving the utility of OCTA somewhat ambiguous. The primary basis for diagnosis\u00a0remains the patient\u2019s history of ocular trauma and the presentation of clinical features. Multimodal imaging continues to be essential for tracking the disease\u2019s progression, identifying recurrences, and evaluating therapeutic responses. Advanced OCT technologies have facilitated the noninvasive assessment of\u00a0retinochoroidal\u00a0microstructural and microvascular alterations in diseases like\u00a0sympathetic ophthalmia\u00a0and Vogt-Koyanagi-Harada. OCTA, in particular, is an increasingly favored instrument in diagnosing and managing choroidal disorders, attesting to its utility in ophthalmic practice. [81]", "contents": "Sympathetic Ophthalmia -- Evaluation -- Optical Coherence Tomography Angiography. Despite\u00a0the advantages as a noninvasive imaging technique, especially for conditions affecting the choriocapillaris, OCTA has limitations in adequately capturing medium and\u00a0large\u00a0choroidal vessel details. Additionally, signal loss and artifacts can complicate the interpretation of flow voids, necessitating careful differentiation and occasionally leaving the utility of OCTA somewhat ambiguous. The primary basis for diagnosis\u00a0remains the patient\u2019s history of ocular trauma and the presentation of clinical features. Multimodal imaging continues to be essential for tracking the disease\u2019s progression, identifying recurrences, and evaluating therapeutic responses. Advanced OCT technologies have facilitated the noninvasive assessment of\u00a0retinochoroidal\u00a0microstructural and microvascular alterations in diseases like\u00a0sympathetic ophthalmia\u00a0and Vogt-Koyanagi-Harada. OCTA, in particular, is an increasingly favored instrument in diagnosing and managing choroidal disorders, attesting to its utility in ophthalmic practice. [81]"}
{"id": "article-151525_54", "title": "Sympathetic Ophthalmia -- Evaluation -- Fluorescein Angiography", "content": "This excellent noninvasive imaging modality provides\u00a0useful\u00a0information for the diagnosis and treatment monitoring of patients with sympathetic ophthalmia. In the acute phase of sympathetic ophthalmia,\u00a02\u00a0patterns\u00a0are seen. The first is nearly identical to the pattern seen in Vogt-Koyanagi-Harada with initial diffuse pinpoint hyperfluorescent spots with late leakage with or without hyperfluorescence of the disc. Another less common variant is initial multiple hypofluorescent spots with late-phase pooling.\u00a0These spots may coalesce under serous retinal detachments in severe disease. [82]", "contents": "Sympathetic Ophthalmia -- Evaluation -- Fluorescein Angiography. This excellent noninvasive imaging modality provides\u00a0useful\u00a0information for the diagnosis and treatment monitoring of patients with sympathetic ophthalmia. In the acute phase of sympathetic ophthalmia,\u00a02\u00a0patterns\u00a0are seen. The first is nearly identical to the pattern seen in Vogt-Koyanagi-Harada with initial diffuse pinpoint hyperfluorescent spots with late leakage with or without hyperfluorescence of the disc. Another less common variant is initial multiple hypofluorescent spots with late-phase pooling.\u00a0These spots may coalesce under serous retinal detachments in severe disease. [82]"}
{"id": "article-151525_55", "title": "Sympathetic Ophthalmia -- Evaluation -- Fluorescein Angiography", "content": "The second acute phase pattern\u00a0resembles\u00a0acute posterior multifocal placoid pigment epitheliopathy (APMPPE), demonstrating initial\u00a0hypofluorescent\u00a0foci that\u00a0are hyperfluorescent in the late phase with staining of the lesions. Unlike APMPPE, the lesions in sympathetic ophthalmia are elevated and mottled in appearance. [83] The initial\u00a0hypofluorescence\u00a0may be secondary to obscuration from Dalen-Fuchs nodules or choroidal inflammation leading to focal obliteration of the choriocapillaris.", "contents": "Sympathetic Ophthalmia -- Evaluation -- Fluorescein Angiography. The second acute phase pattern\u00a0resembles\u00a0acute posterior multifocal placoid pigment epitheliopathy (APMPPE), demonstrating initial\u00a0hypofluorescent\u00a0foci that\u00a0are hyperfluorescent in the late phase with staining of the lesions. Unlike APMPPE, the lesions in sympathetic ophthalmia are elevated and mottled in appearance. [83] The initial\u00a0hypofluorescence\u00a0may be secondary to obscuration from Dalen-Fuchs nodules or choroidal inflammation leading to focal obliteration of the choriocapillaris."}
{"id": "article-151525_56", "title": "Sympathetic Ophthalmia -- Evaluation -- Fluorescein Angiography", "content": "Chronic\u00a0sympathetic ophthalmia findings are\u00a0more variable, depending on the inflammatory sequelae of the disease.\u00a0Nummular scars\u00a0occur\u00a0from focal damage to the\u00a0retinal pigment epithelium and inner choroid, and they present as window defects. [30] Subretinal fibrosis may present with hyperfluorescent staining due to proliferated metaplastic retinal pigment epithelium. [4] [84] The presence of choroidal neovascularization may reveal leakage in the macula.", "contents": "Sympathetic Ophthalmia -- Evaluation -- Fluorescein Angiography. Chronic\u00a0sympathetic ophthalmia findings are\u00a0more variable, depending on the inflammatory sequelae of the disease.\u00a0Nummular scars\u00a0occur\u00a0from focal damage to the\u00a0retinal pigment epithelium and inner choroid, and they present as window defects. [30] Subretinal fibrosis may present with hyperfluorescent staining due to proliferated metaplastic retinal pigment epithelium. [4] [84] The presence of choroidal neovascularization may reveal leakage in the macula."}
{"id": "article-151525_57", "title": "Sympathetic Ophthalmia -- Evaluation -- Indocyanine Green Angiography", "content": "Indocyanine green angiography (ICGA) is instrumental in examining the choroidal vasculature, significantly enhancing our understanding of the pathogenesis of diseases like sympathetic ophthalmia, which primarily affects the choroid. ICGA\u00a0is used\u00a0as an adjunct to fluorescein angiography, given\u00a0the superior ability to assess the choroid and choroidal infiltrates. A common finding in sympathetic ophthalmia on ICGA is multiple hypocyanescent spots corresponding to the hyperfluorescent spots. Histopathological studies of these lesions have confirmed\u00a0the\u00a0spots are caused by cellular infiltrates of the choroid or due to blockage by overlying fluid. [85] These hypocyanescent spots are similar in all phases of\u00a0sympathetic ophthalmia and tend to improve\u00a0with adequate treatment. [68] [86] The hypocyanescent spots may return in late-phase sympathetic ophthalmia, possibly due to choroidal atrophy. [87] Bernasconi and colleagues have further explored these observations, noting that\u00a0the presentation may indicate scarred lesions. In contrast,\u00a0the diminishment signals active inflammatory lesions. Importantly, these hypocyanescent lesions typically resolve with corticosteroid treatment, a change that correlates closely with clinical improvement in patients. This dynamic reflects the critical role of ICGA in guiding the diagnosis and monitoring the treatment response, providing a clearer picture of the choroidal involvement and the effectiveness of therapeutic interventions.", "contents": "Sympathetic Ophthalmia -- Evaluation -- Indocyanine Green Angiography. Indocyanine green angiography (ICGA) is instrumental in examining the choroidal vasculature, significantly enhancing our understanding of the pathogenesis of diseases like sympathetic ophthalmia, which primarily affects the choroid. ICGA\u00a0is used\u00a0as an adjunct to fluorescein angiography, given\u00a0the superior ability to assess the choroid and choroidal infiltrates. A common finding in sympathetic ophthalmia on ICGA is multiple hypocyanescent spots corresponding to the hyperfluorescent spots. Histopathological studies of these lesions have confirmed\u00a0the\u00a0spots are caused by cellular infiltrates of the choroid or due to blockage by overlying fluid. [85] These hypocyanescent spots are similar in all phases of\u00a0sympathetic ophthalmia and tend to improve\u00a0with adequate treatment. [68] [86] The hypocyanescent spots may return in late-phase sympathetic ophthalmia, possibly due to choroidal atrophy. [87] Bernasconi and colleagues have further explored these observations, noting that\u00a0the presentation may indicate scarred lesions. In contrast,\u00a0the diminishment signals active inflammatory lesions. Importantly, these hypocyanescent lesions typically resolve with corticosteroid treatment, a change that correlates closely with clinical improvement in patients. This dynamic reflects the critical role of ICGA in guiding the diagnosis and monitoring the treatment response, providing a clearer picture of the choroidal involvement and the effectiveness of therapeutic interventions."}
{"id": "article-151525_58", "title": "Sympathetic Ophthalmia -- Treatment / Management -- Surgical", "content": "Historically, removal of the injured eye within 14 days of ocular trauma protects the contralateral eye from the onset of sympathetic ophthalmia. [58] When sympathetic ophthalmia occurs, enucleation no longer benefits the sympathizing eye. [29] However,\u00a0the practice of prophylactic enucleation lacks supporting scientific evidence and is based primarily on observation and clinical speculation. [88]", "contents": "Sympathetic Ophthalmia -- Treatment / Management -- Surgical. Historically, removal of the injured eye within 14 days of ocular trauma protects the contralateral eye from the onset of sympathetic ophthalmia. [58] When sympathetic ophthalmia occurs, enucleation no longer benefits the sympathizing eye. [29] However,\u00a0the practice of prophylactic enucleation lacks supporting scientific evidence and is based primarily on observation and clinical speculation. [88]"}
{"id": "article-151525_59", "title": "Sympathetic Ophthalmia -- Treatment / Management -- Surgical", "content": "Sympathetic ophthalmia\u00a0occurs in the sympathizing eye despite removing the traumatic globe. [89] Removing the\u00a0inciting eye\u00a0does not improve the sympathetic eye\u2019s visual acuity. In many patients, the inciting eye may\u00a0have better overall vision. [90] Importantly, in\u00a0most cases of ocular injury where the traumatic globe\u00a0was not removed, patients\u00a0do not develop sympathetic ophthalmia. [91] The decision of when to remove and when to save a severely traumatized eye is difficult. In a study of 660\u00a0traumatic globe injuries, over 98% of injuries\u00a0were successfully repaired\u00a0surgically, and only 13% resulted in\u00a0no light perception vision. Indication for primary removal of the globe only occurred in 1.7% due to the inability to repair the globe. [92] Additionally, patients with\u00a0no light perception vision after ocular trauma regain\u00a0some\u00a0vision in 16% of\u00a0cases. [93]", "contents": "Sympathetic Ophthalmia -- Treatment / Management -- Surgical. Sympathetic ophthalmia\u00a0occurs in the sympathizing eye despite removing the traumatic globe. [89] Removing the\u00a0inciting eye\u00a0does not improve the sympathetic eye\u2019s visual acuity. In many patients, the inciting eye may\u00a0have better overall vision. [90] Importantly, in\u00a0most cases of ocular injury where the traumatic globe\u00a0was not removed, patients\u00a0do not develop sympathetic ophthalmia. [91] The decision of when to remove and when to save a severely traumatized eye is difficult. In a study of 660\u00a0traumatic globe injuries, over 98% of injuries\u00a0were successfully repaired\u00a0surgically, and only 13% resulted in\u00a0no light perception vision. Indication for primary removal of the globe only occurred in 1.7% due to the inability to repair the globe. [92] Additionally, patients with\u00a0no light perception vision after ocular trauma regain\u00a0some\u00a0vision in 16% of\u00a0cases. [93]"}
{"id": "article-151525_60", "title": "Sympathetic Ophthalmia -- Treatment / Management -- Surgical", "content": "Furthermore, the negative psychological impact of losing an eye cannot be understated and should\u00a0be\u00a0considered\u00a0before enucleation or evisceration. Patients\u00a0often experience body dysmorphia, depression, and increased anxiety from losing\u00a0an eye. [94] Cosmetic benefits include saving the\u00a0phthisical eye since the eye often retains\u00a0full\u00a0movement, and the irregular anterior surface better supports an overlying ocular prosthesis. [88]", "contents": "Sympathetic Ophthalmia -- Treatment / Management -- Surgical. Furthermore, the negative psychological impact of losing an eye cannot be understated and should\u00a0be\u00a0considered\u00a0before enucleation or evisceration. Patients\u00a0often experience body dysmorphia, depression, and increased anxiety from losing\u00a0an eye. [94] Cosmetic benefits include saving the\u00a0phthisical eye since the eye often retains\u00a0full\u00a0movement, and the irregular anterior surface better supports an overlying ocular prosthesis. [88]"}
{"id": "article-151525_61", "title": "Sympathetic Ophthalmia -- Treatment / Management -- Surgical", "content": "In cases where the ruptured globe is beyond repair, removal of the eye via evisceration or enucleation\u00a0is the only option. Significant debate exists as to which procedure is\u00a0more appropriate. Critics of evisceration argue that evisceration poses a potential risk for disseminating unsuspected uveal malignancy and a theoretical risk of causing sympathetic ophthalmia due to remnant uveal tissues. [95] However, a more recent large retrospective study of patients\u00a0showed no cases of sympathetic ophthalmia after evisceration. [62] Evisceration\u00a0is\u00a0favored since\u00a0this is\u00a0technically easier, and preserving the sclera can provide a barrier to prevent the orbital spread of infection. Evisceration\u00a0may also provide a cosmetic and functional advantage for the patient.", "contents": "Sympathetic Ophthalmia -- Treatment / Management -- Surgical. In cases where the ruptured globe is beyond repair, removal of the eye via evisceration or enucleation\u00a0is the only option. Significant debate exists as to which procedure is\u00a0more appropriate. Critics of evisceration argue that evisceration poses a potential risk for disseminating unsuspected uveal malignancy and a theoretical risk of causing sympathetic ophthalmia due to remnant uveal tissues. [95] However, a more recent large retrospective study of patients\u00a0showed no cases of sympathetic ophthalmia after evisceration. [62] Evisceration\u00a0is\u00a0favored since\u00a0this is\u00a0technically easier, and preserving the sclera can provide a barrier to prevent the orbital spread of infection. Evisceration\u00a0may also provide a cosmetic and functional advantage for the patient."}
{"id": "article-151525_62", "title": "Sympathetic Ophthalmia -- Treatment / Management -- Medical", "content": "Patients with sympathetic ophthalmia who\u00a0undergo prompt treatment with high-dose steroids and immunomodulatory agents have a better chance for\u00a0positive visual outcomes. [96] The initial treatment for sympathetic ophthalmia typically involves administering high-dose systemic corticosteroids, with the specific regimen tailored according to the clinical presentation, disease severity, and initial visual acuity. In 1995, the National Eye Institute highlighted the efficacy of such high-dose systemic anti-inflammatory therapy, recommending corticosteroids at dosages ranging from 0.5 to 2 mg/kg/day of prednisolone to preserve vision.", "contents": "Sympathetic Ophthalmia -- Treatment / Management -- Medical. Patients with sympathetic ophthalmia who\u00a0undergo prompt treatment with high-dose steroids and immunomodulatory agents have a better chance for\u00a0positive visual outcomes. [96] The initial treatment for sympathetic ophthalmia typically involves administering high-dose systemic corticosteroids, with the specific regimen tailored according to the clinical presentation, disease severity, and initial visual acuity. In 1995, the National Eye Institute highlighted the efficacy of such high-dose systemic anti-inflammatory therapy, recommending corticosteroids at dosages ranging from 0.5 to 2 mg/kg/day of prednisolone to preserve vision."}
{"id": "article-151525_63", "title": "Sympathetic Ophthalmia -- Treatment / Management -- Medical", "content": "Upon diagnosis of sympathetic ophthalmia, initiating patients on high-dose intravenous corticosteroids at a dose of 1 to 2 mg/kg/day with adjunct topical cycloplegics and corticosteroids is recommended. [97] Improvements in retinal findings have been noted\u00a0soon after the initiation of corticosteroids. [98] In very severe cases, intravenous pulse methylprednisolone can be considered at a dose of 1 gram/day for\u00a03\u00a0days. [7] Patients should remain on steroids for a minimum of 3 months with a very slow taper if improvement\u00a0is noted.", "contents": "Sympathetic Ophthalmia -- Treatment / Management -- Medical. Upon diagnosis of sympathetic ophthalmia, initiating patients on high-dose intravenous corticosteroids at a dose of 1 to 2 mg/kg/day with adjunct topical cycloplegics and corticosteroids is recommended. [97] Improvements in retinal findings have been noted\u00a0soon after the initiation of corticosteroids. [98] In very severe cases, intravenous pulse methylprednisolone can be considered at a dose of 1 gram/day for\u00a03\u00a0days. [7] Patients should remain on steroids for a minimum of 3 months with a very slow taper if improvement\u00a0is noted."}
{"id": "article-151525_64", "title": "Sympathetic Ophthalmia -- Treatment / Management -- Medical", "content": "Other immunosuppressive agents may be warranted if a patient experiences recurrence or worsened inflammation. Systemic corticosteroids may have significant complications, including uncontrolled diabetes, adrenal insufficiency, osteoporosis, and increased infection risk.\u00a0Intravitreal steroids can\u00a0be considered\u00a0to\u00a0avoid some of these systemic complications and enable a targeted high concentration of the drug at the site of the disease.\u00a0Studies have shown that intravitreal steroid therapy controls uveitic macular edema effectively. [99] [100] The results of another study\u00a0suggested the use of\u00a0intravitreal dexamethasone implants in place of systemic therapy; however, this is currently not the standard of care. [101]", "contents": "Sympathetic Ophthalmia -- Treatment / Management -- Medical. Other immunosuppressive agents may be warranted if a patient experiences recurrence or worsened inflammation. Systemic corticosteroids may have significant complications, including uncontrolled diabetes, adrenal insufficiency, osteoporosis, and increased infection risk.\u00a0Intravitreal steroids can\u00a0be considered\u00a0to\u00a0avoid some of these systemic complications and enable a targeted high concentration of the drug at the site of the disease.\u00a0Studies have shown that intravitreal steroid therapy controls uveitic macular edema effectively. [99] [100] The results of another study\u00a0suggested the use of\u00a0intravitreal dexamethasone implants in place of systemic therapy; however, this is currently not the standard of care. [101]"}
{"id": "article-151525_65", "title": "Sympathetic Ophthalmia -- Treatment / Management -- Medical", "content": "For severe cases characterized by iris nodules, pronounced granulomatous panuveitis, and serous retinal detachments, intravenous corticosteroid therapy is usually preferred. High-dose intravenous pulse therapy, often using methylprednisolone at\u00a01\u00a0g/day for\u00a03\u00a0days, quickly reduces significant pathological changes like vitritis, multifocal retinal detachments, and inflammation in the anterior chamber. Depending on the patient\u2019s response, this intravenous treatment might extend for\u00a05 to\u00a07 days.", "contents": "Sympathetic Ophthalmia -- Treatment / Management -- Medical. For severe cases characterized by iris nodules, pronounced granulomatous panuveitis, and serous retinal detachments, intravenous corticosteroid therapy is usually preferred. High-dose intravenous pulse therapy, often using methylprednisolone at\u00a01\u00a0g/day for\u00a03\u00a0days, quickly reduces significant pathological changes like vitritis, multifocal retinal detachments, and inflammation in the anterior chamber. Depending on the patient\u2019s response, this intravenous treatment might extend for\u00a05 to\u00a07 days."}
{"id": "article-151525_66", "title": "Sympathetic Ophthalmia -- Treatment / Management -- Medical", "content": "However,\u00a0the aggressive form of treatment\u00a0has potential risks, including rapid changes in blood pressure and blood glucose levels, along with serious side effects such as the possible reactivation of pulmonary tuberculosis. As such, these initial intensive treatments\u00a0should\u00a0be carefully managed, weighing the risks against the benefits. Following the control of the acute inflammatory phase, the regimen usually transitions to a lower dose of systemic corticosteroids, starting at 1 mg/kg/day of prednisolone, gradually tapered over\u00a02 to\u00a03 months. This duration allows for an adequate assessment of the treatment\u2019s effectiveness. Should further surgical interventions become necessary, increasing the corticosteroid dosage may be required to manage inflammation effectively. [102]", "contents": "Sympathetic Ophthalmia -- Treatment / Management -- Medical. However,\u00a0the aggressive form of treatment\u00a0has potential risks, including rapid changes in blood pressure and blood glucose levels, along with serious side effects such as the possible reactivation of pulmonary tuberculosis. As such, these initial intensive treatments\u00a0should\u00a0be carefully managed, weighing the risks against the benefits. Following the control of the acute inflammatory phase, the regimen usually transitions to a lower dose of systemic corticosteroids, starting at 1 mg/kg/day of prednisolone, gradually tapered over\u00a02 to\u00a03 months. This duration allows for an adequate assessment of the treatment\u2019s effectiveness. Should further surgical interventions become necessary, increasing the corticosteroid dosage may be required to manage inflammation effectively. [102]"}
{"id": "article-151525_67", "title": "Sympathetic Ophthalmia -- Treatment / Management -- Medical", "content": "Immunomodulators can be considered in patients with contraindications to steroid use, significant or intolerable side effects, or uncontrolled disease despite steroid therapy.\u00a0Up to 70% of patients with sympathetic ophthalmia need immunomodulatory therapy. [36] Immunosuppressive therapies are often prescribed for patients with sympathetic ophthalmia to minimize the dependence on prolonged systemic corticosteroid treatment. Typically, a regimen combining corticosteroids with immunosuppressive agents\u00a0is started\u00a0early in the treatment process, allowing sufficient time for the immunosuppressives to take effect. Additionally, alternative immunosuppressive drugs\u00a0are introduced\u00a0if a patient shows intolerance to a specific medication. [103]", "contents": "Sympathetic Ophthalmia -- Treatment / Management -- Medical. Immunomodulators can be considered in patients with contraindications to steroid use, significant or intolerable side effects, or uncontrolled disease despite steroid therapy.\u00a0Up to 70% of patients with sympathetic ophthalmia need immunomodulatory therapy. [36] Immunosuppressive therapies are often prescribed for patients with sympathetic ophthalmia to minimize the dependence on prolonged systemic corticosteroid treatment. Typically, a regimen combining corticosteroids with immunosuppressive agents\u00a0is started\u00a0early in the treatment process, allowing sufficient time for the immunosuppressives to take effect. Additionally, alternative immunosuppressive drugs\u00a0are introduced\u00a0if a patient shows intolerance to a specific medication. [103]"}
{"id": "article-151525_68", "title": "Sympathetic Ophthalmia -- Treatment / Management -- Medical", "content": "A variety of agents are available for the management of sympathetic ophthalmia. Commonly utilized medications include mycophenolate mofetil, azathioprine, cyclosporine, and cyclophosphamide. Cyclophosphamide\u00a0is generally reserved\u00a0for cases resistant to other treatments due to\u00a0the potential for severe systemic side effects.", "contents": "Sympathetic Ophthalmia -- Treatment / Management -- Medical. A variety of agents are available for the management of sympathetic ophthalmia. Commonly utilized medications include mycophenolate mofetil, azathioprine, cyclosporine, and cyclophosphamide. Cyclophosphamide\u00a0is generally reserved\u00a0for cases resistant to other treatments due to\u00a0the potential for severe systemic side effects."}
{"id": "article-151525_69", "title": "Sympathetic Ophthalmia -- Treatment / Management -- Medical", "content": "Most of these medications have significant systemic toxicities and require close monitoring; therefore, consultation with rheumatology or internal medicine specialists may\u00a0be recommended\u00a0for the co-management of these cases. Types of immunomodulators include:", "contents": "Sympathetic Ophthalmia -- Treatment / Management -- Medical. Most of these medications have significant systemic toxicities and require close monitoring; therefore, consultation with rheumatology or internal medicine specialists may\u00a0be recommended\u00a0for the co-management of these cases. Types of immunomodulators include:"}
{"id": "article-151525_70", "title": "Sympathetic Ophthalmia -- Treatment / Management -- Medical", "content": "Cyclosporine\u00a0is a calcineurin inhibitor that inhibits T-cell function. The recommended starting dose is 2.5\u00a0to 5 mg/kg/day. If improvement in a patient is noted for more than\u00a03\u00a0months, a slow taper may\u00a0be initiated, decreasing by 0.5 mg/kg/day every 1 to 2 months. This medication can enable the control of severe inflammation in sympathetic ophthalmia.\u00a0Though well tolerated in children and adolescents, increased side effects\u00a0are noted\u00a0with advanced age.\u00a0Potential side effects include hepatotoxicity, nephrotoxicity, gingival hyperplasia, and hypertension.", "contents": "Sympathetic Ophthalmia -- Treatment / Management -- Medical. Cyclosporine\u00a0is a calcineurin inhibitor that inhibits T-cell function. The recommended starting dose is 2.5\u00a0to 5 mg/kg/day. If improvement in a patient is noted for more than\u00a03\u00a0months, a slow taper may\u00a0be initiated, decreasing by 0.5 mg/kg/day every 1 to 2 months. This medication can enable the control of severe inflammation in sympathetic ophthalmia.\u00a0Though well tolerated in children and adolescents, increased side effects\u00a0are noted\u00a0with advanced age.\u00a0Potential side effects include hepatotoxicity, nephrotoxicity, gingival hyperplasia, and hypertension."}
{"id": "article-151525_71", "title": "Sympathetic Ophthalmia -- Treatment / Management -- Medical", "content": "Azathioprine is an inhibitor of purine synthesis that affects B and T lymphocytes and effectively manages sympathetic ophthalmia. The recommended dose is 1 to 3 mg/kg/day. Given the risk of myelosuppression, close monitoring of complete blood count\u00a0is warranted\u00a0in these patients. Additional potential side effects include hepatotoxicity, pancreatitis, and increased risk for cancer.", "contents": "Sympathetic Ophthalmia -- Treatment / Management -- Medical. Azathioprine is an inhibitor of purine synthesis that affects B and T lymphocytes and effectively manages sympathetic ophthalmia. The recommended dose is 1 to 3 mg/kg/day. Given the risk of myelosuppression, close monitoring of complete blood count\u00a0is warranted\u00a0in these patients. Additional potential side effects include hepatotoxicity, pancreatitis, and increased risk for cancer."}
{"id": "article-151525_72", "title": "Sympathetic Ophthalmia -- Treatment / Management -- Medical", "content": "Mycophenolate mofetil is\u00a0an inhibitor of purine synthesis, better tolerated\u00a0than azathioprine, and has fewer side effects.\u00a0The medication is usually\u00a0dosed at 1 to 3 g/day and must\u00a0be taken\u00a0on an empty stomach.", "contents": "Sympathetic Ophthalmia -- Treatment / Management -- Medical. Mycophenolate mofetil is\u00a0an inhibitor of purine synthesis, better tolerated\u00a0than azathioprine, and has fewer side effects.\u00a0The medication is usually\u00a0dosed at 1 to 3 g/day and must\u00a0be taken\u00a0on an empty stomach."}
{"id": "article-151525_73", "title": "Sympathetic Ophthalmia -- Treatment / Management -- Medical", "content": "Alkylating agents like chlorambucil and cyclophosphamide control inflammation in sympathetic ophthalmia. However, these medications are associated with severe systemic side effects, including hemorrhagic cystitis, myelosuppression, secondary malignancies, and sterility. Therefore, patients should be monitored closely with internal medicine co-management.", "contents": "Sympathetic Ophthalmia -- Treatment / Management -- Medical. Alkylating agents like chlorambucil and cyclophosphamide control inflammation in sympathetic ophthalmia. However, these medications are associated with severe systemic side effects, including hemorrhagic cystitis, myelosuppression, secondary malignancies, and sterility. Therefore, patients should be monitored closely with internal medicine co-management."}
{"id": "article-151525_74", "title": "Sympathetic Ophthalmia -- Treatment / Management -- Medical", "content": "Anti-TNF-\u03b1 biologic agents such as infliximab and adalimumab are gaining traction as potential first-line corticosteroid-sparing agents since they target the specific inflammatory cytokine involved in the pathogenesis of sympathetic ophthalmia. Adalimumab offers the convenience of a subcutaneous injection every\u00a02\u00a0weeks, which can significantly improve a patient\u2019s quality of life. Importantly, before initiating therapy, patients should\u00a0undergo testing for tuberculosis, given the concern for disease reactivation. [4] [104] [105] [106]", "contents": "Sympathetic Ophthalmia -- Treatment / Management -- Medical. Anti-TNF-\u03b1 biologic agents such as infliximab and adalimumab are gaining traction as potential first-line corticosteroid-sparing agents since they target the specific inflammatory cytokine involved in the pathogenesis of sympathetic ophthalmia. Adalimumab offers the convenience of a subcutaneous injection every\u00a02\u00a0weeks, which can significantly improve a patient\u2019s quality of life. Importantly, before initiating therapy, patients should\u00a0undergo testing for tuberculosis, given the concern for disease reactivation. [4] [104] [105] [106]"}
{"id": "article-151525_75", "title": "Sympathetic Ophthalmia -- Differential Diagnosis", "content": "Vogt-Koyanagi-Harada syndrome is a well-delineated bilateral panuveitis that may mimic the presentation of sympathetic ophthalmia both on the clinical exam and in various imaging modalities. However, unlike sympathetic ophthalmia,\u00a0the syndrome is not associated with prior ocular trauma or surgery and tends to follow a more set evolutional disease progression. Classification criteria for the early stage of the syndrome include evidence of either exudative retinal detachment or panuveitis with at least\u00a02\u00a0neurologic signs (headache, tinnitus, dysacusis, meningismus, or cerebrospinal fluid pleocytosis) and no history of prior ocular trauma or ocular surgery. Classification for late-stage includes evidence of early-stage\u00a0syndrome and either the presence of a sunset glow fundus or uveitis with cutaneous findings of vitiligo, poliosis, or alopecia. [107] Of note, systemic neurologic symptoms and cutaneous findings\u00a0are present in patients with sympathetic ophthalmia but with significantly lower frequency. [108]", "contents": "Sympathetic Ophthalmia -- Differential Diagnosis. Vogt-Koyanagi-Harada syndrome is a well-delineated bilateral panuveitis that may mimic the presentation of sympathetic ophthalmia both on the clinical exam and in various imaging modalities. However, unlike sympathetic ophthalmia,\u00a0the syndrome is not associated with prior ocular trauma or surgery and tends to follow a more set evolutional disease progression. Classification criteria for the early stage of the syndrome include evidence of either exudative retinal detachment or panuveitis with at least\u00a02\u00a0neurologic signs (headache, tinnitus, dysacusis, meningismus, or cerebrospinal fluid pleocytosis) and no history of prior ocular trauma or ocular surgery. Classification for late-stage includes evidence of early-stage\u00a0syndrome and either the presence of a sunset glow fundus or uveitis with cutaneous findings of vitiligo, poliosis, or alopecia. [107] Of note, systemic neurologic symptoms and cutaneous findings\u00a0are present in patients with sympathetic ophthalmia but with significantly lower frequency. [108]"}
{"id": "article-151525_76", "title": "Sympathetic Ophthalmia -- Differential Diagnosis", "content": "Vogt-Koyanagi-Harada\u00a0syndrome demonstrates a higher prevalence in certain groups, including the Asian, Hispanic, and Middle Eastern populations, and affects women with a higher frequency. [109] Sympathetic ophthalmia has no geographic predilection and occurs more in men than women. Patients with bilateral uveitis must also undergo a full systemic workup to rule out masquerading diseases such as lymphoma, tuberculosis, syphilis, and sarcoidosis. [7] [110] [111] Lymphoma workup should include a thorough neurologic evaluation, and a vitreous sample should be obtained for cytologic analysis and flow cytometry. Tuberculosis, syphilis, and sarcoidosis usually present with systemic signs and symptoms, which should\u00a0be\u00a0elicited\u00a0when\u00a0obtaining\u00a0a history. Bacterial, viral, and fungal endophthalmitis may also be on the differential but typically do not involve both eyes. If the suspicion of endophthalmitis persists, a vitreous sample should\u00a0be obtained\u00a0for further testing.", "contents": "Sympathetic Ophthalmia -- Differential Diagnosis. Vogt-Koyanagi-Harada\u00a0syndrome demonstrates a higher prevalence in certain groups, including the Asian, Hispanic, and Middle Eastern populations, and affects women with a higher frequency. [109] Sympathetic ophthalmia has no geographic predilection and occurs more in men than women. Patients with bilateral uveitis must also undergo a full systemic workup to rule out masquerading diseases such as lymphoma, tuberculosis, syphilis, and sarcoidosis. [7] [110] [111] Lymphoma workup should include a thorough neurologic evaluation, and a vitreous sample should be obtained for cytologic analysis and flow cytometry. Tuberculosis, syphilis, and sarcoidosis usually present with systemic signs and symptoms, which should\u00a0be\u00a0elicited\u00a0when\u00a0obtaining\u00a0a history. Bacterial, viral, and fungal endophthalmitis may also be on the differential but typically do not involve both eyes. If the suspicion of endophthalmitis persists, a vitreous sample should\u00a0be obtained\u00a0for further testing."}
{"id": "article-151525_77", "title": "Sympathetic Ophthalmia -- Differential Diagnosis", "content": "The list of differential diagnoses includes:", "contents": "Sympathetic Ophthalmia -- Differential Diagnosis. The list of differential diagnoses includes:"}
{"id": "article-151525_78", "title": "Sympathetic Ophthalmia -- Differential Diagnosis", "content": "Vogt-Koyanagi-Harada disease: This\u00a0is a panuveitis that includes serous retinal detachments and may present with systemic symptoms such as vitiligo, alopecia, and hearing loss.", "contents": "Sympathetic Ophthalmia -- Differential Diagnosis. Vogt-Koyanagi-Harada disease: This\u00a0is a panuveitis that includes serous retinal detachments and may present with systemic symptoms such as vitiligo, alopecia, and hearing loss."}
{"id": "article-151525_79", "title": "Sympathetic Ophthalmia -- Differential Diagnosis", "content": "Sarcoidosis: A\u00a0systemic granulomatous disease can present with granulomatous uveitis mimicking\u00a0sympathetic ophthalmia and may\u00a0involve other organ systems.", "contents": "Sympathetic Ophthalmia -- Differential Diagnosis. Sarcoidosis: A\u00a0systemic granulomatous disease can present with granulomatous uveitis mimicking\u00a0sympathetic ophthalmia and may\u00a0involve other organ systems."}
{"id": "article-151525_80", "title": "Sympathetic Ophthalmia -- Differential Diagnosis", "content": "Intraocular lymphoma: This malignancy can cause uveitis and retinal detachment, requiring a biopsy for a definitive diagnosis.", "contents": "Sympathetic Ophthalmia -- Differential Diagnosis. Intraocular lymphoma: This malignancy can cause uveitis and retinal detachment, requiring a biopsy for a definitive diagnosis."}
{"id": "article-151525_81", "title": "Sympathetic Ophthalmia -- Differential Diagnosis", "content": "Infectious uveitis : This includes tuberculosis, syphilis, and viral infections such as HSV and cytomegalovirus (CMV), which can cause panuveitis.", "contents": "Sympathetic Ophthalmia -- Differential Diagnosis. Infectious uveitis : This includes tuberculosis, syphilis, and viral infections such as HSV and cytomegalovirus (CMV), which can cause panuveitis."}
{"id": "article-151525_82", "title": "Sympathetic Ophthalmia -- Differential Diagnosis", "content": "Beh\u00e7et disease: A systemic vasculitis that can cause panuveitis, oral and genital ulcers,\u00a0and skin lesions.", "contents": "Sympathetic Ophthalmia -- Differential Diagnosis. Beh\u00e7et disease: A systemic vasculitis that can cause panuveitis, oral and genital ulcers,\u00a0and skin lesions."}
{"id": "article-151525_83", "title": "Sympathetic Ophthalmia -- Differential Diagnosis", "content": "Uveitis associated with juvenile idiopathic arthritis: Juvenile idiopathic arthritis can be associated with chronic uveitis, especially in younger patients.", "contents": "Sympathetic Ophthalmia -- Differential Diagnosis. Uveitis associated with juvenile idiopathic arthritis: Juvenile idiopathic arthritis can be associated with chronic uveitis, especially in younger patients."}
{"id": "article-151525_84", "title": "Sympathetic Ophthalmia -- Differential Diagnosis", "content": "Posterior scleritis: The condition\u00a0may cause painful inflammation\u00a0with similar fundus changes to sympathetic ophthalmia.", "contents": "Sympathetic Ophthalmia -- Differential Diagnosis. Posterior scleritis: The condition\u00a0may cause painful inflammation\u00a0with similar fundus changes to sympathetic ophthalmia."}
{"id": "article-151525_85", "title": "Sympathetic Ophthalmia -- Differential Diagnosis", "content": "Ocular toxoplasmosis: This\u00a0is infectious uveitis that can lead to retinal necrosis and choroiditis, sometimes similar to sympathetic ophthalmia.", "contents": "Sympathetic Ophthalmia -- Differential Diagnosis. Ocular toxoplasmosis: This\u00a0is infectious uveitis that can lead to retinal necrosis and choroiditis, sometimes similar to sympathetic ophthalmia."}
{"id": "article-151525_86", "title": "Sympathetic Ophthalmia -- Differential Diagnosis", "content": "Endophthalmitis: Acute inflammation of the intraocular cavities, usually due to infection that can mimic the panuveitis seen in sympathetic ophthalmia.", "contents": "Sympathetic Ophthalmia -- Differential Diagnosis. Endophthalmitis: Acute inflammation of the intraocular cavities, usually due to infection that can mimic the panuveitis seen in sympathetic ophthalmia."}
{"id": "article-151525_87", "title": "Sympathetic Ophthalmia -- Differential Diagnosis", "content": "Posterior uveitis of other causes: Idiopathic or drug-induced causes.", "contents": "Sympathetic Ophthalmia -- Differential Diagnosis. Posterior uveitis of other causes: Idiopathic or drug-induced causes."}
{"id": "article-151525_88", "title": "Sympathetic Ophthalmia -- Differential Diagnosis", "content": "Masquerade syndromes: Conditions\u00a0that mimic intraocular inflammation but are not due to true uveitis, such as retinoblastoma in children or melanoma in adults.", "contents": "Sympathetic Ophthalmia -- Differential Diagnosis. Masquerade syndromes: Conditions\u00a0that mimic intraocular inflammation but are not due to true uveitis, such as retinoblastoma in children or melanoma in adults."}
{"id": "article-151525_89", "title": "Sympathetic Ophthalmia -- Differential Diagnosis", "content": "Multifocal choroiditis with panuveitis: This condition presents multiple choroidal lesions and inflammation resembling sympathetic ophthalmia. [112] [113] [114] [115] [116] [117]", "contents": "Sympathetic Ophthalmia -- Differential Diagnosis. Multifocal choroiditis with panuveitis: This condition presents multiple choroidal lesions and inflammation resembling sympathetic ophthalmia. [112] [113] [114] [115] [116] [117]"}
{"id": "article-151525_90", "title": "Sympathetic Ophthalmia -- Differential Diagnosis", "content": "When assessing a patient, a comprehensive clinical examination, detailed patient history, and relevant ancillary tests are crucial for differentiating from these other conditions. An accurate diagnosis is vital for providing the correct treatment and improving the prognosis.", "contents": "Sympathetic Ophthalmia -- Differential Diagnosis. When assessing a patient, a comprehensive clinical examination, detailed patient history, and relevant ancillary tests are crucial for differentiating from these other conditions. An accurate diagnosis is vital for providing the correct treatment and improving the prognosis."}
{"id": "article-151525_91", "title": "Sympathetic Ophthalmia -- Treatment Planning", "content": "Sympathetic ophthalmia does not have a universally accepted staging system like some other diseases, largely due to\u00a0its rarity. However, the clinical presentation of the disease can be described in terms of\u00a0the severity and the extent of ocular involvement. A potential approach to staging could consider the following factors:", "contents": "Sympathetic Ophthalmia -- Treatment Planning. Sympathetic ophthalmia does not have a universally accepted staging system like some other diseases, largely due to\u00a0its rarity. However, the clinical presentation of the disease can be described in terms of\u00a0the severity and the extent of ocular involvement. A potential approach to staging could consider the following factors:"}
{"id": "article-151525_92", "title": "Sympathetic Ophthalmia -- Treatment Planning -- Onset of Symptoms", "content": "Acute : The sudden appearance of symptoms following trauma or surgery to the fellow eye, typically within days to months. Delayed: Symptoms manifesting months to years after the inciting event. [3] [118]", "contents": "Sympathetic Ophthalmia -- Treatment Planning -- Onset of Symptoms. Acute : The sudden appearance of symptoms following trauma or surgery to the fellow eye, typically within days to months. Delayed: Symptoms manifesting months to years after the inciting event. [3] [118]"}
{"id": "article-151525_93", "title": "Sympathetic Ophthalmia -- Treatment Planning -- Clinical Features", "content": "Mild: Mild uveitis with slight discomfort, minimal visual impairment, and few inflammatory signs Moderate: More pronounced uveitis with moderate pain and visual impairment,\u00a0keratitic\u00a0precipitates, and vitreous haze Severe: Intense inflammation with significant pain, photophobia, severe vision loss, and the presence of exudative retinal detachments or choroidal neovascularization [119]", "contents": "Sympathetic Ophthalmia -- Treatment Planning -- Clinical Features. Mild: Mild uveitis with slight discomfort, minimal visual impairment, and few inflammatory signs Moderate: More pronounced uveitis with moderate pain and visual impairment,\u00a0keratitic\u00a0precipitates, and vitreous haze Severe: Intense inflammation with significant pain, photophobia, severe vision loss, and the presence of exudative retinal detachments or choroidal neovascularization [119]"}
{"id": "article-151525_94", "title": "Sympathetic Ophthalmia -- Treatment Planning -- Anatomical Involvement", "content": "Anterior uveitis: Inflammation primarily in the iris and ciliary body Intermediate uveitis : Inflammation centered in the vitreous Posterior uveitis: Inflammation affecting the retina and choroid Panuveitis: Involvement of all segments of the uvea [120]", "contents": "Sympathetic Ophthalmia -- Treatment Planning -- Anatomical Involvement. Anterior uveitis: Inflammation primarily in the iris and ciliary body Intermediate uveitis : Inflammation centered in the vitreous Posterior uveitis: Inflammation affecting the retina and choroid Panuveitis: Involvement of all segments of the uvea [120]"}
{"id": "article-151525_95", "title": "Sympathetic Ophthalmia -- Treatment Planning -- The Extent\u00a0of Systemic Immune Response", "content": "Localized: Inflammation confined to the eyes with no systemic immune reaction Systemic: Evidence of a more generalized autoimmune response potentially affecting other organs [121]", "contents": "Sympathetic Ophthalmia -- Treatment Planning -- The Extent\u00a0of Systemic Immune Response. Localized: Inflammation confined to the eyes with no systemic immune reaction Systemic: Evidence of a more generalized autoimmune response potentially affecting other organs [121]"}
{"id": "article-151525_96", "title": "Sympathetic Ophthalmia -- Treatment Planning -- Complications", "content": "Stage I: No complications, inflammation controlled with medication Stage II: Development of complications such as cataracts or glaucoma, controllable with treatment Stage III: Complications such as chronic cystoid macular edema, optic atrophy, or subretinal neovascular membranes leading to irreversible vision loss [122]", "contents": "Sympathetic Ophthalmia -- Treatment Planning -- Complications. Stage I: No complications, inflammation controlled with medication Stage II: Development of complications such as cataracts or glaucoma, controllable with treatment Stage III: Complications such as chronic cystoid macular edema, optic atrophy, or subretinal neovascular membranes leading to irreversible vision loss [122]"}
{"id": "article-151525_97", "title": "Sympathetic Ophthalmia -- Treatment Planning -- Response to Treatment", "content": "Responsive: The disease responds to initial therapy without\u00a0recurrence Refractory: Disease not adequately controlled with standard therapy, requiring more aggressive treatment or resulting in chronic condition [123]", "contents": "Sympathetic Ophthalmia -- Treatment Planning -- Response to Treatment. Responsive: The disease responds to initial therapy without\u00a0recurrence Refractory: Disease not adequately controlled with standard therapy, requiring more aggressive treatment or resulting in chronic condition [123]"}
{"id": "article-151525_98", "title": "Sympathetic Ophthalmia -- Treatment Planning", "content": "This\u00a0staging is not officially recognized and is more for descriptive purposes, as clinicians often tailor treatment to the individual patient\u2019s condition rather than a specific stage. Due to the variability of the disease, a multidisciplinary approach\u00a0is often required\u00a0for management, and staging may be more complex than in other diseases with well-defined classification systems. [124]", "contents": "Sympathetic Ophthalmia -- Treatment Planning. This\u00a0staging is not officially recognized and is more for descriptive purposes, as clinicians often tailor treatment to the individual patient\u2019s condition rather than a specific stage. Due to the variability of the disease, a multidisciplinary approach\u00a0is often required\u00a0for management, and staging may be more complex than in other diseases with well-defined classification systems. [124]"}
{"id": "article-151525_99", "title": "Sympathetic Ophthalmia -- Toxicity and Adverse Effect Management", "content": "Managing the toxicity and adverse effects of treatment for sympathetic ophthalmia is an important aspect of patient care. Treatment regimens, particularly those involving long-term corticosteroid use and immunosuppressive agents, can lead to various side effects. Here are general strategies for managing such complications:", "contents": "Sympathetic Ophthalmia -- Toxicity and Adverse Effect Management. Managing the toxicity and adverse effects of treatment for sympathetic ophthalmia is an important aspect of patient care. Treatment regimens, particularly those involving long-term corticosteroid use and immunosuppressive agents, can lead to various side effects. Here are general strategies for managing such complications:"}
{"id": "article-151525_100", "title": "Sympathetic Ophthalmia -- Toxicity and Adverse Effect Management -- Corticosteroid-Induced Side Effects", "content": "Osteoporosis prevention : Calcium, vitamin D supplements, and bone density monitoring Hyperglycemia control: Blood sugar level monitoring and collaborating with a primary care physician for diabetes management Increased infection risk: Educate patients on signs of infection; possibly prescribe prophylactic antibiotics for specific situations Cataract and glaucoma: Regular eye examinations, pressure monitoring, and surgeries as needed", "contents": "Sympathetic Ophthalmia -- Toxicity and Adverse Effect Management -- Corticosteroid-Induced Side Effects. Osteoporosis prevention : Calcium, vitamin D supplements, and bone density monitoring Hyperglycemia control: Blood sugar level monitoring and collaborating with a primary care physician for diabetes management Increased infection risk: Educate patients on signs of infection; possibly prescribe prophylactic antibiotics for specific situations Cataract and glaucoma: Regular eye examinations, pressure monitoring, and surgeries as needed"}
{"id": "article-151525_101", "title": "Sympathetic Ophthalmia -- Toxicity and Adverse Effect Management -- Immunosuppressive Drug Monitoring", "content": "Liver and kidney function: Regular blood tests to monitor liver enzymes and kidney function due to the potential hepatotoxicity and nephrotoxicity of medications like methotrexate and cyclosporine Blood dyscrasias: Complete blood counts to monitor for anemia, leukopenia, and thrombocytopenia Infection surveillance: Patients on immunosuppressive therapy are more susceptible to opportunistic infections", "contents": "Sympathetic Ophthalmia -- Toxicity and Adverse Effect Management -- Immunosuppressive Drug Monitoring. Liver and kidney function: Regular blood tests to monitor liver enzymes and kidney function due to the potential hepatotoxicity and nephrotoxicity of medications like methotrexate and cyclosporine Blood dyscrasias: Complete blood counts to monitor for anemia, leukopenia, and thrombocytopenia Infection surveillance: Patients on immunosuppressive therapy are more susceptible to opportunistic infections"}
{"id": "article-151525_102", "title": "Sympathetic Ophthalmia -- Toxicity and Adverse Effect Management -- Biologic Agents", "content": "Injection site reactions: Local care and possibly adjusting the administration technique Risk of reactivation of tuberculosis : Screening for tuberculosis before starting therapy with biologic agents, particularly TNF-\u03b1 inhibitors Demyelinating disorders: Neurological assessment for any new-onset neurological symptoms", "contents": "Sympathetic Ophthalmia -- Toxicity and Adverse Effect Management -- Biologic Agents. Injection site reactions: Local care and possibly adjusting the administration technique Risk of reactivation of tuberculosis : Screening for tuberculosis before starting therapy with biologic agents, particularly TNF-\u03b1 inhibitors Demyelinating disorders: Neurological assessment for any new-onset neurological symptoms"}
{"id": "article-151525_103", "title": "Sympathetic Ophthalmia -- Toxicity and Adverse Effect Management -- General Health Maintenance", "content": "Nutritional support: A balanced diet may help manage weight and maintain overall health. Physical activity: Encourage weight-bearing exercises to maintain bone density and muscle strength. Psychosocial support: Access to mental health professionals to address any psychological effects of chronic illness and vision loss is\u00a0important.", "contents": "Sympathetic Ophthalmia -- Toxicity and Adverse Effect Management -- General Health Maintenance. Nutritional support: A balanced diet may help manage weight and maintain overall health. Physical activity: Encourage weight-bearing exercises to maintain bone density and muscle strength. Psychosocial support: Access to mental health professionals to address any psychological effects of chronic illness and vision loss is\u00a0important."}
{"id": "article-151525_104", "title": "Sympathetic Ophthalmia -- Toxicity and Adverse Effect Management -- Patient Education", "content": "Medication adherence: Stress the importance of not abruptly stopping medications to avoid acute rebound effects. Adverse\u00a0effect awareness: Educate patients about potential\u00a0adverse\u00a0effects and when to seek medical help.", "contents": "Sympathetic Ophthalmia -- Toxicity and Adverse Effect Management -- Patient Education. Medication adherence: Stress the importance of not abruptly stopping medications to avoid acute rebound effects. Adverse\u00a0effect awareness: Educate patients about potential\u00a0adverse\u00a0effects and when to seek medical help."}
{"id": "article-151525_105", "title": "Sympathetic Ophthalmia -- Toxicity and Adverse Effect Management", "content": "Treating clinicians must\u00a0tailor management plans based on the specific medications used and the patient\u2019s overall health profile. Regular and comprehensive monitoring for side effects can mitigate the risks associated with treating sympathetic ophthalmia. [125] [126] [127] [128] [129]", "contents": "Sympathetic Ophthalmia -- Toxicity and Adverse Effect Management. Treating clinicians must\u00a0tailor management plans based on the specific medications used and the patient\u2019s overall health profile. Regular and comprehensive monitoring for side effects can mitigate the risks associated with treating sympathetic ophthalmia. [125] [126] [127] [128] [129]"}
{"id": "article-151525_106", "title": "Sympathetic Ophthalmia -- Staging", "content": "Sympathetic ophthalmia does not have a universally accepted staging system like some other diseases, largely due to\u00a0its rarity. However, the clinical presentation of the disease can be described in terms of\u00a0the severity and the extent of ocular involvement. A potential approach to staging could consider the following factors:", "contents": "Sympathetic Ophthalmia -- Staging. Sympathetic ophthalmia does not have a universally accepted staging system like some other diseases, largely due to\u00a0its rarity. However, the clinical presentation of the disease can be described in terms of\u00a0the severity and the extent of ocular involvement. A potential approach to staging could consider the following factors:"}
{"id": "article-151525_107", "title": "Sympathetic Ophthalmia -- Staging -- Onset of Symptoms", "content": "Acute : The sudden appearance of symptoms following trauma or surgery to the fellow eye, typically within days to months. Delayed: Symptoms manifesting months to years after the inciting event [3] [118]", "contents": "Sympathetic Ophthalmia -- Staging -- Onset of Symptoms. Acute : The sudden appearance of symptoms following trauma or surgery to the fellow eye, typically within days to months. Delayed: Symptoms manifesting months to years after the inciting event [3] [118]"}
{"id": "article-151525_108", "title": "Sympathetic Ophthalmia -- Staging -- Clinical Features", "content": "Mild: Mild uveitis with slight discomfort, minimal visual impairment, and few inflammatory signs Moderate: More pronounced uveitis with moderate pain and visual impairment, keratitic precipitates, and vitreous haze. Severe: Intense inflammation with significant pain, photophobia, severe vision loss, and the presence of exudative retinal detachments or choroidal neovascularization. [119]", "contents": "Sympathetic Ophthalmia -- Staging -- Clinical Features. Mild: Mild uveitis with slight discomfort, minimal visual impairment, and few inflammatory signs Moderate: More pronounced uveitis with moderate pain and visual impairment, keratitic precipitates, and vitreous haze. Severe: Intense inflammation with significant pain, photophobia, severe vision loss, and the presence of exudative retinal detachments or choroidal neovascularization. [119]"}
{"id": "article-151525_109", "title": "Sympathetic Ophthalmia -- Staging -- Anatomical Involvement", "content": "Anterior uveitis: Inflammation primarily in the iris and ciliary body Intermediate uveitis : Inflammation centered in the vitreous Posterior uveitis: Inflammation affecting the retina and choroid Panuveitis: Involvement of all segments of the uvea [120] The Extent of Systemic Immune Response Localized: Inflammation confined to the eyes with no systemic immune reaction Systemic: Evidence of a more generalized autoimmune response potentially affecting other organs [121]", "contents": "Sympathetic Ophthalmia -- Staging -- Anatomical Involvement. Anterior uveitis: Inflammation primarily in the iris and ciliary body Intermediate uveitis : Inflammation centered in the vitreous Posterior uveitis: Inflammation affecting the retina and choroid Panuveitis: Involvement of all segments of the uvea [120] The Extent of Systemic Immune Response Localized: Inflammation confined to the eyes with no systemic immune reaction Systemic: Evidence of a more generalized autoimmune response potentially affecting other organs [121]"}
{"id": "article-151525_110", "title": "Sympathetic Ophthalmia -- Staging -- Complications", "content": "Stage I: No complications, inflammation controlled with medication Stage II: Development of complications such as cataracts or glaucoma, controllable with treatment Stage III: Complications such as chronic cystoid macular edema, optic atrophy, or subretinal neovascular membranes leading to irreversible vision loss [122]", "contents": "Sympathetic Ophthalmia -- Staging -- Complications. Stage I: No complications, inflammation controlled with medication Stage II: Development of complications such as cataracts or glaucoma, controllable with treatment Stage III: Complications such as chronic cystoid macular edema, optic atrophy, or subretinal neovascular membranes leading to irreversible vision loss [122]"}
{"id": "article-151525_111", "title": "Sympathetic Ophthalmia -- Staging -- Response to Treatment", "content": "Responsive: The disease responds to initial therapy without recurrence Refractory: Disease not adequately controlled with standard therapy, requiring more aggressive treatment or resulting in chronic condition [123]", "contents": "Sympathetic Ophthalmia -- Staging -- Response to Treatment. Responsive: The disease responds to initial therapy without recurrence Refractory: Disease not adequately controlled with standard therapy, requiring more aggressive treatment or resulting in chronic condition [123]"}
{"id": "article-151525_112", "title": "Sympathetic Ophthalmia -- Staging", "content": "This\u00a0staging is not officially recognized and is more for descriptive purposes, as clinicians often tailor treatment to the individual patient\u2019s condition rather than a specific stage. Due to the variability of the disease, a multidisciplinary approach is often required for management, and staging may be more complex than in other diseases with well-defined classification systems. [124]", "contents": "Sympathetic Ophthalmia -- Staging. This\u00a0staging is not officially recognized and is more for descriptive purposes, as clinicians often tailor treatment to the individual patient\u2019s condition rather than a specific stage. Due to the variability of the disease, a multidisciplinary approach is often required for management, and staging may be more complex than in other diseases with well-defined classification systems. [124]"}
{"id": "article-151525_113", "title": "Sympathetic Ophthalmia -- Prognosis", "content": "Early initiation of immunomodulatory therapy is\u00a0key\u00a0for improving visual outcomes in patients with sympathetic ophthalmia. Studies show that the initiation of treatment within 15 days of symptom onset\u00a0caused over 85% of sympathizing eyes to achieve visual acuity of 20/40 or better and over 20% of\u00a0inciting eyes to reach at least 20/80.\u00a0However, patients will need lifelong follow-up to avoid vision-threatening complications, given the relapsing nature of this disease. [82] [97] The prognosis of sympathetic ophthalmia\u00a0varies significantly and largely depends on how quickly and effectively the inflammation is controlled. Here are several factors that can impact the prognosis:", "contents": "Sympathetic Ophthalmia -- Prognosis. Early initiation of immunomodulatory therapy is\u00a0key\u00a0for improving visual outcomes in patients with sympathetic ophthalmia. Studies show that the initiation of treatment within 15 days of symptom onset\u00a0caused over 85% of sympathizing eyes to achieve visual acuity of 20/40 or better and over 20% of\u00a0inciting eyes to reach at least 20/80.\u00a0However, patients will need lifelong follow-up to avoid vision-threatening complications, given the relapsing nature of this disease. [82] [97] The prognosis of sympathetic ophthalmia\u00a0varies significantly and largely depends on how quickly and effectively the inflammation is controlled. Here are several factors that can impact the prognosis:"}
{"id": "article-151525_114", "title": "Sympathetic Ophthalmia -- Prognosis", "content": "Timing of treatment: Early diagnosis and prompt treatment initiation are crucial for a better prognosis. Delayed treatment can lead to irreversible ocular damage.", "contents": "Sympathetic Ophthalmia -- Prognosis. Timing of treatment: Early diagnosis and prompt treatment initiation are crucial for a better prognosis. Delayed treatment can lead to irreversible ocular damage."}
{"id": "article-151525_115", "title": "Sympathetic Ophthalmia -- Prognosis", "content": "Severity of inflammation: The severity of inflammation at the time of presentation is a\u00a0key\u00a0determinant. More severe inflammation is associated with a poorer prognosis.", "contents": "Sympathetic Ophthalmia -- Prognosis. Severity of inflammation: The severity of inflammation at the time of presentation is a\u00a0key\u00a0determinant. More severe inflammation is associated with a poorer prognosis."}
{"id": "article-151525_116", "title": "Sympathetic Ophthalmia -- Prognosis", "content": "Response to treatment: A\u00a0positive response to steroids and immunosuppressive therapy can help preserve vision and improve the long-term prognosis.", "contents": "Sympathetic Ophthalmia -- Prognosis. Response to treatment: A\u00a0positive response to steroids and immunosuppressive therapy can help preserve vision and improve the long-term prognosis."}
{"id": "article-151525_117", "title": "Sympathetic Ophthalmia -- Prognosis", "content": "Complications: The development of complications such as cataracts, glaucoma, or subretinal neovascularization can worsen the prognosis. Management of these complications is an essential part of improving the overall outcome.", "contents": "Sympathetic Ophthalmia -- Prognosis. Complications: The development of complications such as cataracts, glaucoma, or subretinal neovascularization can worsen the prognosis. Management of these complications is an essential part of improving the overall outcome."}
{"id": "article-151525_118", "title": "Sympathetic Ophthalmia -- Prognosis", "content": "Recurrence: Recurrent episodes of inflammation can lead to cumulative damage to the eye, resulting in a poorer visual prognosis.", "contents": "Sympathetic Ophthalmia -- Prognosis. Recurrence: Recurrent episodes of inflammation can lead to cumulative damage to the eye, resulting in a poorer visual prognosis."}
{"id": "article-151525_119", "title": "Sympathetic Ophthalmia -- Prognosis", "content": "Systemic disease: If sympathetic ophthalmia is associated with systemic autoimmune disorders, managing the overall systemic condition is also necessary for a better prognosis.", "contents": "Sympathetic Ophthalmia -- Prognosis. Systemic disease: If sympathetic ophthalmia is associated with systemic autoimmune disorders, managing the overall systemic condition is also necessary for a better prognosis."}
{"id": "article-151525_120", "title": "Sympathetic Ophthalmia -- Prognosis", "content": "Adherence to treatment plan: Patient adherence to a long-term treatment plan, including systemic medications with potential side effects, is crucial for maintaining disease control and improving outcomes. [62] [129] [130] [131] [132] [133] [134]", "contents": "Sympathetic Ophthalmia -- Prognosis. Adherence to treatment plan: Patient adherence to a long-term treatment plan, including systemic medications with potential side effects, is crucial for maintaining disease control and improving outcomes. [62] [129] [130] [131] [132] [133] [134]"}
{"id": "article-151525_121", "title": "Sympathetic Ophthalmia -- Prognosis", "content": "Despite these considerations, modern immunosuppressive treatments have improved the prognosis of sympathetic ophthalmia compared to the pre-steroid era. However, due to the potential for chronicity and recurrence, some patients may experience a decline in visual function over time.\u00a0Current research and newer therapies continue to\u00a0facilitate\u00a0improvements in the management and prognosis. Regular follow-up with an ophthalmologist and, when appropriate, a rheumatologist or immunologist is essential.", "contents": "Sympathetic Ophthalmia -- Prognosis. Despite these considerations, modern immunosuppressive treatments have improved the prognosis of sympathetic ophthalmia compared to the pre-steroid era. However, due to the potential for chronicity and recurrence, some patients may experience a decline in visual function over time.\u00a0Current research and newer therapies continue to\u00a0facilitate\u00a0improvements in the management and prognosis. Regular follow-up with an ophthalmologist and, when appropriate, a rheumatologist or immunologist is essential."}
{"id": "article-151525_122", "title": "Sympathetic Ophthalmia -- Complications", "content": "The most common complications seen with sympathetic ophthalmia are cataract development and ocular hypertension, leading to glaucoma. [29] Cataract development can result from recurrent or persistent intraocular inflammation and long-term corticosteroid therapy. Cataract extraction for patients with sympathetic ophthalmia is safe with meticulous surgical planning and careful preoperative and postoperative management of intraocular inflammation. [135] However, final visual acuity depends on the extent of the patient\u2019s posterior segment disease. Ocular hypertension can occur in acute inflammation causing\u00a0trabeculitis\u00a0or in the chronic setting secondary to extensive peripheral anterior synechiae formation or pupillary block secondary to posterior synechiae. [136]", "contents": "Sympathetic Ophthalmia -- Complications. The most common complications seen with sympathetic ophthalmia are cataract development and ocular hypertension, leading to glaucoma. [29] Cataract development can result from recurrent or persistent intraocular inflammation and long-term corticosteroid therapy. Cataract extraction for patients with sympathetic ophthalmia is safe with meticulous surgical planning and careful preoperative and postoperative management of intraocular inflammation. [135] However, final visual acuity depends on the extent of the patient\u2019s posterior segment disease. Ocular hypertension can occur in acute inflammation causing\u00a0trabeculitis\u00a0or in the chronic setting secondary to extensive peripheral anterior synechiae formation or pupillary block secondary to posterior synechiae. [136]"}
{"id": "article-151525_123", "title": "Sympathetic Ophthalmia -- Complications", "content": "Chronic serous retinal detachments can lead to subretinal fibrosis, severely compromising vision if the macula is involved. Compromised choroid and\u00a0retinal pigment epithelium\u00a0can lead to choroidal neovascularization, which may require anti-vascular endothelial growth factor intravitreal injections. [137] Bevacizumab, ranibizumab, or aflibercept are equally appropriate for treating\u00a0choroidal neovascularization\u00a0in patients with sympathetic ophthalmia. [3] Other potential side effects of chronic disease include choroidal atrophy and phthisis. [4] Sympathetic ophthalmia can lead to several severe ocular complications, some of which threaten vision. The complications are often a result of the underlying inflammatory process or the side effects of the intensive treatments required to control the disease. Common complications include the following:", "contents": "Sympathetic Ophthalmia -- Complications. Chronic serous retinal detachments can lead to subretinal fibrosis, severely compromising vision if the macula is involved. Compromised choroid and\u00a0retinal pigment epithelium\u00a0can lead to choroidal neovascularization, which may require anti-vascular endothelial growth factor intravitreal injections. [137] Bevacizumab, ranibizumab, or aflibercept are equally appropriate for treating\u00a0choroidal neovascularization\u00a0in patients with sympathetic ophthalmia. [3] Other potential side effects of chronic disease include choroidal atrophy and phthisis. [4] Sympathetic ophthalmia can lead to several severe ocular complications, some of which threaten vision. The complications are often a result of the underlying inflammatory process or the side effects of the intensive treatments required to control the disease. Common complications include the following:"}
{"id": "article-151525_124", "title": "Sympathetic Ophthalmia -- Complications", "content": "Glaucoma: Increased intraocular pressure can lead to glaucoma either due to the disease or as a side effect of steroid therapy.", "contents": "Sympathetic Ophthalmia -- Complications. Glaucoma: Increased intraocular pressure can lead to glaucoma either due to the disease or as a side effect of steroid therapy."}
{"id": "article-151525_125", "title": "Sympathetic Ophthalmia -- Complications", "content": "Macular edema: Inflammation can cause fluid accumulation in the retina, particularly in the macula, leading to cystoid macular edema, impairing central vision.", "contents": "Sympathetic Ophthalmia -- Complications. Macular edema: Inflammation can cause fluid accumulation in the retina, particularly in the macula, leading to cystoid macular edema, impairing central vision."}
{"id": "article-151525_126", "title": "Sympathetic Ophthalmia -- Complications", "content": "Choroidal neovascularization: Abnormal blood vessel growth under the retina, stimulated by chronic inflammation, can cause bleeding and scarring, threatening vision.", "contents": "Sympathetic Ophthalmia -- Complications. Choroidal neovascularization: Abnormal blood vessel growth under the retina, stimulated by chronic inflammation, can cause bleeding and scarring, threatening vision."}
{"id": "article-151525_127", "title": "Sympathetic Ophthalmia -- Complications", "content": "Optic atrophy: Prolonged inflammation can damage the optic nerve, leading to optic atrophy and permanent vision loss.", "contents": "Sympathetic Ophthalmia -- Complications. Optic atrophy: Prolonged inflammation can damage the optic nerve, leading to optic atrophy and permanent vision loss."}
{"id": "article-151525_128", "title": "Sympathetic Ophthalmia -- Complications", "content": "Band keratopathy: Deposition of calcium in the cornea can occur as a chronic response to inflammation.", "contents": "Sympathetic Ophthalmia -- Complications. Band keratopathy: Deposition of calcium in the cornea can occur as a chronic response to inflammation."}
{"id": "article-151525_129", "title": "Sympathetic Ophthalmia -- Complications", "content": "Epiretinal membrane formation: Scar tissue may form on the retina\u2019s surface, distorting vision.", "contents": "Sympathetic Ophthalmia -- Complications. Epiretinal membrane formation: Scar tissue may form on the retina\u2019s surface, distorting vision."}
{"id": "article-151525_130", "title": "Sympathetic Ophthalmia -- Complications", "content": "Scleral and corneal thinning: Chronic inflammation can lead to the thinning of the sclera and cornea, potentially leading to structural weaknesses.", "contents": "Sympathetic Ophthalmia -- Complications. Scleral and corneal thinning: Chronic inflammation can lead to the thinning of the sclera and cornea, potentially leading to structural weaknesses."}
{"id": "article-151525_131", "title": "Sympathetic Ophthalmia -- Complications", "content": "Uveitic glaucoma: A specific type of glaucoma that arises due to uveitis can be\u00a0difficult\u00a0to manage because the eye is already compromised.", "contents": "Sympathetic Ophthalmia -- Complications. Uveitic glaucoma: A specific type of glaucoma that arises due to uveitis can be\u00a0difficult\u00a0to manage because the eye is already compromised."}
{"id": "article-151525_132", "title": "Sympathetic Ophthalmia -- Complications", "content": "Phthisis bulbi: In severe, end-stage cases, the eye\u00a0is atrophic, shrunken, and non-functional. [138] [139] [140]", "contents": "Sympathetic Ophthalmia -- Complications. Phthisis bulbi: In severe, end-stage cases, the eye\u00a0is atrophic, shrunken, and non-functional. [138] [139] [140]"}
{"id": "article-151525_133", "title": "Sympathetic Ophthalmia -- Postoperative and Rehabilitation Care", "content": "Postoperative and rehabilitation care for patients with sympathetic ophthalmia is multifaceted. The care\u00a0is designed\u00a0to manage the inflammation, prevent recurrence, address complications, and aid the patient in adapting to any visual changes. Here are some of the critical components of postoperative and rehabilitation care:", "contents": "Sympathetic Ophthalmia -- Postoperative and Rehabilitation Care. Postoperative and rehabilitation care for patients with sympathetic ophthalmia is multifaceted. The care\u00a0is designed\u00a0to manage the inflammation, prevent recurrence, address complications, and aid the patient in adapting to any visual changes. Here are some of the critical components of postoperative and rehabilitation care:"}
{"id": "article-151525_134", "title": "Sympathetic Ophthalmia -- Postoperative and Rehabilitation Care", "content": "Medication management: Adjusting and monitoring immunosuppressive medications to manage inflammation without causing significant side effects", "contents": "Sympathetic Ophthalmia -- Postoperative and Rehabilitation Care. Medication management: Adjusting and monitoring immunosuppressive medications to manage inflammation without causing significant side effects"}
{"id": "article-151525_135", "title": "Sympathetic Ophthalmia -- Postoperative and Rehabilitation Care", "content": "Slow and careful tapering of corticosteroids: Using topical anti-inflammatory medications as needed to control ocular surface inflammation", "contents": "Sympathetic Ophthalmia -- Postoperative and Rehabilitation Care. Slow and careful tapering of corticosteroids: Using topical anti-inflammatory medications as needed to control ocular surface inflammation"}
{"id": "article-151525_136", "title": "Sympathetic Ophthalmia -- Postoperative and Rehabilitation Care", "content": "Monitoring for complications: Regular ophthalmic exams to detect and treat cataracts, glaucoma, macular edema, or retinal detachments (And monitoring intraocular pressure and adjusting glaucoma medications as needed.)", "contents": "Sympathetic Ophthalmia -- Postoperative and Rehabilitation Care. Monitoring for complications: Regular ophthalmic exams to detect and treat cataracts, glaucoma, macular edema, or retinal detachments (And monitoring intraocular pressure and adjusting glaucoma medications as needed.)"}
{"id": "article-151525_137", "title": "Sympathetic Ophthalmia -- Postoperative and Rehabilitation Care", "content": "Visual rehabilitation: Low vision aids and adaptive technologies to help patients maximize their remaining vision", "contents": "Sympathetic Ophthalmia -- Postoperative and Rehabilitation Care. Visual rehabilitation: Low vision aids and adaptive technologies to help patients maximize their remaining vision"}
{"id": "article-151525_138", "title": "Sympathetic Ophthalmia -- Postoperative and Rehabilitation Care", "content": "Referral to low vision specialists for rehabilitation strategies: Orientation and mobility training for patients with significant vision loss", "contents": "Sympathetic Ophthalmia -- Postoperative and Rehabilitation Care. Referral to low vision specialists for rehabilitation strategies: Orientation and mobility training for patients with significant vision loss"}
{"id": "article-151525_139", "title": "Sympathetic Ophthalmia -- Postoperative and Rehabilitation Care", "content": "Patient education: Teaching patients about the signs of infection, inflammation, or increased intraocular pressure should prompt immediate medical attention and\u00a0provide\u00a0information on the chronic nature of\u00a0sympathetic ophthalmia\u00a0and the importance of adhering to follow-up schedules and medication regimens", "contents": "Sympathetic Ophthalmia -- Postoperative and Rehabilitation Care. Patient education: Teaching patients about the signs of infection, inflammation, or increased intraocular pressure should prompt immediate medical attention and\u00a0provide\u00a0information on the chronic nature of\u00a0sympathetic ophthalmia\u00a0and the importance of adhering to follow-up schedules and medication regimens"}
{"id": "article-151525_140", "title": "Sympathetic Ophthalmia -- Postoperative and Rehabilitation Care", "content": "Physical and occupational therapy: If vision loss is significant, physical and occupational therapy\u00a0is necessary to assist the patient in adapting to changes in vision and maintaining independence", "contents": "Sympathetic Ophthalmia -- Postoperative and Rehabilitation Care. Physical and occupational therapy: If vision loss is significant, physical and occupational therapy\u00a0is necessary to assist the patient in adapting to changes in vision and maintaining independence"}
{"id": "article-151525_141", "title": "Sympathetic Ophthalmia -- Postoperative and Rehabilitation Care", "content": "Psychological support: Psychological or psychiatric support to address issues such as depression or anxiety that can accompany chronic illness and vision loss and\u00a0connect\u00a0patients with support groups and other resources for\u00a0visual impairment.", "contents": "Sympathetic Ophthalmia -- Postoperative and Rehabilitation Care. Psychological support: Psychological or psychiatric support to address issues such as depression or anxiety that can accompany chronic illness and vision loss and\u00a0connect\u00a0patients with support groups and other resources for\u00a0visual impairment."}
{"id": "article-151525_142", "title": "Sympathetic Ophthalmia -- Postoperative and Rehabilitation Care", "content": "Lifestyle adjustments: Counseling on ultraviolet protection to reduce further ocular damage and nutritional guidance to support overall eye health", "contents": "Sympathetic Ophthalmia -- Postoperative and Rehabilitation Care. Lifestyle adjustments: Counseling on ultraviolet protection to reduce further ocular damage and nutritional guidance to support overall eye health"}
{"id": "article-151525_143", "title": "Sympathetic Ophthalmia -- Postoperative and Rehabilitation Care", "content": "Systemic health maintenance: Collaborating with primary care physicians and other specialists to manage comorbid conditions and the systemic side effects of long-term immunosuppression", "contents": "Sympathetic Ophthalmia -- Postoperative and Rehabilitation Care. Systemic health maintenance: Collaborating with primary care physicians and other specialists to manage comorbid conditions and the systemic side effects of long-term immunosuppression"}
{"id": "article-151525_144", "title": "Sympathetic Ophthalmia -- Postoperative and Rehabilitation Care", "content": "Surgical interventions: Planning for any additional surgeries that may be necessary due to complications such as cataracts or glaucoma", "contents": "Sympathetic Ophthalmia -- Postoperative and Rehabilitation Care. Surgical interventions: Planning for any additional surgeries that may be necessary due to complications such as cataracts or glaucoma"}
{"id": "article-151525_145", "title": "Sympathetic Ophthalmia -- Postoperative and Rehabilitation Care", "content": "Documentation and communication: Keeping detailed medical records to document the patient\u2019s progress and responses to treatment and ensuring clear communication between all healthcare team members, including the patient and family [130] [141] [142] [143] [144] [145] [146]", "contents": "Sympathetic Ophthalmia -- Postoperative and Rehabilitation Care. Documentation and communication: Keeping detailed medical records to document the patient\u2019s progress and responses to treatment and ensuring clear communication between all healthcare team members, including the patient and family [130] [141] [142] [143] [144] [145] [146]"}
{"id": "article-151525_146", "title": "Sympathetic Ophthalmia -- Postoperative and Rehabilitation Care", "content": "Effective postoperative and rehabilitation care requires a coordinated effort among ophthalmologists, primary care physicians, rehabilitation specialists, mental health professionals, and the patient and their family or caregivers. This comprehensive approach is essential to achieving the best possible outcome for patients with sympathetic ophthalmia.", "contents": "Sympathetic Ophthalmia -- Postoperative and Rehabilitation Care. Effective postoperative and rehabilitation care requires a coordinated effort among ophthalmologists, primary care physicians, rehabilitation specialists, mental health professionals, and the patient and their family or caregivers. This comprehensive approach is essential to achieving the best possible outcome for patients with sympathetic ophthalmia."}
{"id": "article-151525_147", "title": "Sympathetic Ophthalmia -- Consultations", "content": "Here are the consultations that might be required:", "contents": "Sympathetic Ophthalmia -- Consultations. Here are the consultations that might be required:"}
{"id": "article-151525_148", "title": "Sympathetic Ophthalmia -- Consultations", "content": "Ophthalmologist: A comprehensive evaluation by an ophthalmologist is essential.\u00a0This\u00a0may include an anterior segment surgeon, a vitreoretinal specialist, and a uveitis specialist.", "contents": "Sympathetic Ophthalmia -- Consultations. Ophthalmologist: A comprehensive evaluation by an ophthalmologist is essential.\u00a0This\u00a0may include an anterior segment surgeon, a vitreoretinal specialist, and a uveitis specialist."}
{"id": "article-151525_149", "title": "Sympathetic Ophthalmia -- Consultations", "content": "Rheumatologist or immunologist: These professionals manage immunosuppressive therapy and monitor\u00a0for systemic autoimmune responses.", "contents": "Sympathetic Ophthalmia -- Consultations. Rheumatologist or immunologist: These professionals manage immunosuppressive therapy and monitor\u00a0for systemic autoimmune responses."}
{"id": "article-151525_150", "title": "Sympathetic Ophthalmia -- Consultations", "content": "Infectious disease: Assess the risk of reactivating latent infections like tuberculosis before initiating immunosuppressive therapy, particularly with biological agents.", "contents": "Sympathetic Ophthalmia -- Consultations. Infectious disease: Assess the risk of reactivating latent infections like tuberculosis before initiating immunosuppressive therapy, particularly with biological agents."}
{"id": "article-151525_151", "title": "Sympathetic Ophthalmia -- Consultations", "content": "Endocrinologist: If the patient is on long-term corticosteroids, an endocrinologist can help manage steroid-induced side effects such as diabetes, osteoporosis, and adrenal insufficiency.", "contents": "Sympathetic Ophthalmia -- Consultations. Endocrinologist: If the patient is on long-term corticosteroids, an endocrinologist can help manage steroid-induced side effects such as diabetes, osteoporosis, and adrenal insufficiency."}
{"id": "article-151525_152", "title": "Sympathetic Ophthalmia -- Consultations", "content": "Glaucoma specialist: These specialists manage\u00a0increased intraocular pressure secondary to or a side effect of corticosteroid therapy.", "contents": "Sympathetic Ophthalmia -- Consultations. Glaucoma specialist: These specialists manage\u00a0increased intraocular pressure secondary to or a side effect of corticosteroid therapy."}
{"id": "article-151525_153", "title": "Sympathetic Ophthalmia -- Consultations", "content": "Neurologist: A neurologist may be helpful if neurological symptoms occur, especially considering that\u00a0sympathetic ophthalmia\u00a0is associated with other autoimmune conditions that affect the central nervous system.", "contents": "Sympathetic Ophthalmia -- Consultations. Neurologist: A neurologist may be helpful if neurological symptoms occur, especially considering that\u00a0sympathetic ophthalmia\u00a0is associated with other autoimmune conditions that affect the central nervous system."}
{"id": "article-151525_154", "title": "Sympathetic Ophthalmia -- Consultations", "content": "Low vision specialist: These specialists assist with visual rehabilitation and using aids and adaptive devices.", "contents": "Sympathetic Ophthalmia -- Consultations. Low vision specialist: These specialists assist with visual rehabilitation and using aids and adaptive devices."}
{"id": "article-151525_155", "title": "Sympathetic Ophthalmia -- Consultations", "content": "Occupational therapist: This therapist helps the patient adapt to changes in vision and maintain independence in daily activities.", "contents": "Sympathetic Ophthalmia -- Consultations. Occupational therapist: This therapist helps the patient adapt to changes in vision and maintain independence in daily activities."}
{"id": "article-151525_156", "title": "Sympathetic Ophthalmia -- Consultations", "content": "Psychologist or psychiatrist: A psychologist or psychiatrist may be helpful for supporting the psychological impact of chronic illness and potential vision loss.", "contents": "Sympathetic Ophthalmia -- Consultations. Psychologist or psychiatrist: A psychologist or psychiatrist may be helpful for supporting the psychological impact of chronic illness and potential vision loss."}
{"id": "article-151525_157", "title": "Sympathetic Ophthalmia -- Consultations", "content": "Social worker: Social workers assist with healthcare navigation and access to community resources and support systems.", "contents": "Sympathetic Ophthalmia -- Consultations. Social worker: Social workers assist with healthcare navigation and access to community resources and support systems."}
{"id": "article-151525_158", "title": "Sympathetic Ophthalmia -- Consultations", "content": "Physical therapist: If severe vision loss affects mobility, a physical therapist can help develop new strategies for safe movement and independence.", "contents": "Sympathetic Ophthalmia -- Consultations. Physical therapist: If severe vision loss affects mobility, a physical therapist can help develop new strategies for safe movement and independence."}
{"id": "article-151525_159", "title": "Sympathetic Ophthalmia -- Consultations", "content": "Nutritionist: A nutritionist can provide dietary advice that may help manage medication side effects and overall health.", "contents": "Sympathetic Ophthalmia -- Consultations. Nutritionist: A nutritionist can provide dietary advice that may help manage medication side effects and overall health."}
{"id": "article-151525_160", "title": "Sympathetic Ophthalmia -- Consultations", "content": "Pain management specialist: A pain management specialist may be necessary if the patient experiences chronic pain related to sympathetic ophthalmia or the treatment.", "contents": "Sympathetic Ophthalmia -- Consultations. Pain management specialist: A pain management specialist may be necessary if the patient experiences chronic pain related to sympathetic ophthalmia or the treatment."}
{"id": "article-151525_161", "title": "Sympathetic Ophthalmia -- Consultations", "content": "Primary care physician: The primary care physician coordinates care, manages comorbidities, and monitors the patient\u2019s health during treatment. [147]", "contents": "Sympathetic Ophthalmia -- Consultations. Primary care physician: The primary care physician coordinates care, manages comorbidities, and monitors the patient\u2019s health during treatment. [147]"}
{"id": "article-151525_162", "title": "Sympathetic Ophthalmia -- Deterrence and Patient Education", "content": "Sympathetic ophthalmia is a severe bilateral uveitis resulting in permanent vision loss if appropriate therapy\u00a0is not initiated\u00a0immediately. Patients who have suffered any traumatic ocular injury should\u00a0be counseled\u00a0on the potential risk of this condition, especially within the first year of injury.\u00a0Patients should contact\u00a0their ophthalmologist or go to the nearest emergency room if\u00a0they experience pain, redness, or vision loss in either eye. [3]", "contents": "Sympathetic Ophthalmia -- Deterrence and Patient Education. Sympathetic ophthalmia is a severe bilateral uveitis resulting in permanent vision loss if appropriate therapy\u00a0is not initiated\u00a0immediately. Patients who have suffered any traumatic ocular injury should\u00a0be counseled\u00a0on the potential risk of this condition, especially within the first year of injury.\u00a0Patients should contact\u00a0their ophthalmologist or go to the nearest emergency room if\u00a0they experience pain, redness, or vision loss in either eye. [3]"}
{"id": "article-151525_163", "title": "Sympathetic Ophthalmia -- Deterrence and Patient Education", "content": "Clinicians\u00a0of higher-risk intraocular surgery, such as vitreoretinal surgeons, should also consider discussing the risks of sympathetic ophthalmia with their patients. Given that the inflammation in sympathetic ophthalmia may be chronic and relapsing, patients should also\u00a0be educated\u00a0on recognizing signs and symptoms of recurrence, including worsening vision, photophobia, eye pain, redness, and irritation. [7] Patient education for sympathetic ophthalmia is paramount and involves several key points:", "contents": "Sympathetic Ophthalmia -- Deterrence and Patient Education. Clinicians\u00a0of higher-risk intraocular surgery, such as vitreoretinal surgeons, should also consider discussing the risks of sympathetic ophthalmia with their patients. Given that the inflammation in sympathetic ophthalmia may be chronic and relapsing, patients should also\u00a0be educated\u00a0on recognizing signs and symptoms of recurrence, including worsening vision, photophobia, eye pain, redness, and irritation. [7] Patient education for sympathetic ophthalmia is paramount and involves several key points:"}
{"id": "article-151525_164", "title": "Sympathetic Ophthalmia -- Deterrence and Patient Education", "content": "Understanding the condition : Patients should be educated about the disease\u2019s autoimmune nature, its effect on both eyes and the importance of monitoring for symptoms,\u00a0though\u00a0only\u00a01\u00a0eye is initially injured.", "contents": "Sympathetic Ophthalmia -- Deterrence and Patient Education. Understanding the condition : Patients should be educated about the disease\u2019s autoimmune nature, its effect on both eyes and the importance of monitoring for symptoms,\u00a0though\u00a0only\u00a01\u00a0eye is initially injured."}
{"id": "article-151525_165", "title": "Sympathetic Ophthalmia -- Deterrence and Patient Education", "content": "Preventive measures: Patients\u00a0should be informed about the importance of wearing protective eyewear to prevent ocular trauma, a risk factor for developing the condition.", "contents": "Sympathetic Ophthalmia -- Deterrence and Patient Education. Preventive measures: Patients\u00a0should be informed about the importance of wearing protective eyewear to prevent ocular trauma, a risk factor for developing the condition."}
{"id": "article-151525_166", "title": "Sympathetic Ophthalmia -- Deterrence and Patient Education", "content": "Symptom awareness: Educating patients on the symptoms, such as the sudden onset of vision loss, pain, or redness, necessitating immediate medical attention is vital.", "contents": "Sympathetic Ophthalmia -- Deterrence and Patient Education. Symptom awareness: Educating patients on the symptoms, such as the sudden onset of vision loss, pain, or redness, necessitating immediate medical attention is vital."}
{"id": "article-151525_167", "title": "Sympathetic Ophthalmia -- Deterrence and Patient Education", "content": "Importance of follow-up : Regular follow-up visits are essential to monitor the effectiveness of therapy and make any necessary adjustments.", "contents": "Sympathetic Ophthalmia -- Deterrence and Patient Education. Importance of follow-up : Regular follow-up visits are essential to monitor the effectiveness of therapy and make any necessary adjustments."}
{"id": "article-151525_168", "title": "Sympathetic Ophthalmia -- Deterrence and Patient Education", "content": "Medication adherence: The significance of adhering to prescribed medication regimens,\u00a0though symptoms improve, to prevent relapses is\u00a0important.", "contents": "Sympathetic Ophthalmia -- Deterrence and Patient Education. Medication adherence: The significance of adhering to prescribed medication regimens,\u00a0though symptoms improve, to prevent relapses is\u00a0important."}
{"id": "article-151525_169", "title": "Sympathetic Ophthalmia -- Deterrence and Patient Education", "content": "Managing adverse events: This section provides information on possible side effects of treatments, particularly corticosteroids and immunosuppressants, and when to contact a\u00a0clinician if these occur.", "contents": "Sympathetic Ophthalmia -- Deterrence and Patient Education. Managing adverse events: This section provides information on possible side effects of treatments, particularly corticosteroids and immunosuppressants, and when to contact a\u00a0clinician if these occur."}
{"id": "article-151525_170", "title": "Sympathetic Ophthalmia -- Deterrence and Patient Education", "content": "Long-term management: This\u00a0includes understanding that this condition may require long-term or lifelong management and highlighting the importance of maintaining a relationship with treating clinicians.", "contents": "Sympathetic Ophthalmia -- Deterrence and Patient Education. Long-term management: This\u00a0includes understanding that this condition may require long-term or lifelong management and highlighting the importance of maintaining a relationship with treating clinicians."}
{"id": "article-151525_171", "title": "Sympathetic Ophthalmia -- Deterrence and Patient Education", "content": "Support resources: Providing resources for support groups or counseling services to help patients cope with the emotional and psychological impact of chronic disease and potential vision loss. [148] [149] [150]", "contents": "Sympathetic Ophthalmia -- Deterrence and Patient Education. Support resources: Providing resources for support groups or counseling services to help patients cope with the emotional and psychological impact of chronic disease and potential vision loss. [148] [149] [150]"}
{"id": "article-151525_172", "title": "Sympathetic Ophthalmia -- Deterrence and Patient Education", "content": "Ensure that patients with sympathetic ophthalmia are well-informed about their condition and its management. This will make them active participants, leading to better outcomes and a reduced risk of complications.", "contents": "Sympathetic Ophthalmia -- Deterrence and Patient Education. Ensure that patients with sympathetic ophthalmia are well-informed about their condition and its management. This will make them active participants, leading to better outcomes and a reduced risk of complications."}
{"id": "article-151525_173", "title": "Sympathetic Ophthalmia -- Pearls and Other Issues", "content": "In managing sympathetic ophthalmia, depth of knowledge and vigilance are crucial:", "contents": "Sympathetic Ophthalmia -- Pearls and Other Issues. In managing sympathetic ophthalmia, depth of knowledge and vigilance are crucial:"}
{"id": "article-151525_174", "title": "Sympathetic Ophthalmia -- Pearls and Other Issues -- Pearls", "content": "Swift intervention following ocular trauma or surgery can significantly alter prognosis. Sympathetic ophthalmia can masquerade as other forms of uveitis, so a thorough history is imperative.", "contents": "Sympathetic Ophthalmia -- Pearls and Other Issues -- Pearls. Swift intervention following ocular trauma or surgery can significantly alter prognosis. Sympathetic ophthalmia can masquerade as other forms of uveitis, so a thorough history is imperative."}
{"id": "article-151525_175", "title": "Sympathetic Ophthalmia -- Pearls and Other Issues -- Disposition", "content": "Lifelong monitoring may be necessary, as the disease can recur after quiescence. Patients often require a team for management, including ophthalmologists, rheumatologists, and potentially immunologists.", "contents": "Sympathetic Ophthalmia -- Pearls and Other Issues -- Disposition. Lifelong monitoring may be necessary, as the disease can recur after quiescence. Patients often require a team for management, including ophthalmologists, rheumatologists, and potentially immunologists."}
{"id": "article-151525_176", "title": "Sympathetic Ophthalmia -- Pearls and Other Issues -- Pitfalls", "content": "Delay in treatment or misdiagnosis can lead to a cascade of ocular complications and vision loss. Insufficient dosing or early cessation of immunosuppressive therapy can result in disease flares.", "contents": "Sympathetic Ophthalmia -- Pearls and Other Issues -- Pitfalls. Delay in treatment or misdiagnosis can lead to a cascade of ocular complications and vision loss. Insufficient dosing or early cessation of immunosuppressive therapy can result in disease flares."}
{"id": "article-151525_177", "title": "Sympathetic Ophthalmia -- Pearls and Other Issues -- Prevention", "content": "Prompt and appropriate management of ocular injuries and informed decision-making regarding enucleation in specific cases can reduce risk. Preoperative patient education on the risks of elective intraocular surgery is crucial.", "contents": "Sympathetic Ophthalmia -- Pearls and Other Issues -- Prevention. Prompt and appropriate management of ocular injuries and informed decision-making regarding enucleation in specific cases can reduce risk. Preoperative patient education on the risks of elective intraocular surgery is crucial."}
{"id": "article-151525_178", "title": "Sympathetic Ophthalmia -- Pearls and Other Issues -- Additional Considerations", "content": "Counseling on the chronicity of the disease and the commitment to long-term treatment is essential. Developing an individualized plan for medication management, considering comorbidities and the risk of systemic side effects, enhances patient adherence and outcomes. [7] [9] [151] [152] [153]", "contents": "Sympathetic Ophthalmia -- Pearls and Other Issues -- Additional Considerations. Counseling on the chronicity of the disease and the commitment to long-term treatment is essential. Developing an individualized plan for medication management, considering comorbidities and the risk of systemic side effects, enhances patient adherence and outcomes. [7] [9] [151] [152] [153]"}
{"id": "article-151525_179", "title": "Sympathetic Ophthalmia -- Enhancing Healthcare Team Outcomes", "content": "Sympathetic ophthalmia\u00a0is a clinical diagnosis requiring a carefully detailed history and physical exam to parse out the diagnosis from potential masqueraders. Ophthalmologists almost always care for patients with sudden eye pain or vision loss. Still, they may not be the first\u00a0clinician to\u00a0evaluate the patient. Nurses, optometrists, and emergency medicine clinicians need a baseline understanding of this\u00a0disease and when\u00a0to refer for subspecialty care. The patient will also require an interprofessional team\u00a0that includes\u00a0internal medicine clinicians and pharmacists to co-manage\u00a0their disease, given the need for long-term steroid\u00a0use or immunomodulation. Enhancing healthcare outcomes for patients with sympathetic ophthalmia demands a collaborative, multi-disciplinary approach:", "contents": "Sympathetic Ophthalmia -- Enhancing Healthcare Team Outcomes. Sympathetic ophthalmia\u00a0is a clinical diagnosis requiring a carefully detailed history and physical exam to parse out the diagnosis from potential masqueraders. Ophthalmologists almost always care for patients with sudden eye pain or vision loss. Still, they may not be the first\u00a0clinician to\u00a0evaluate the patient. Nurses, optometrists, and emergency medicine clinicians need a baseline understanding of this\u00a0disease and when\u00a0to refer for subspecialty care. The patient will also require an interprofessional team\u00a0that includes\u00a0internal medicine clinicians and pharmacists to co-manage\u00a0their disease, given the need for long-term steroid\u00a0use or immunomodulation. Enhancing healthcare outcomes for patients with sympathetic ophthalmia demands a collaborative, multi-disciplinary approach:"}
{"id": "article-151525_180", "title": "Sympathetic Ophthalmia -- Enhancing Healthcare Team Outcomes -- Physicians and Ophthalmologists", "content": "Lead the diagnosis and management plan Regularly evaluate treatment efficacy and adjust as needed", "contents": "Sympathetic Ophthalmia -- Enhancing Healthcare Team Outcomes -- Physicians and Ophthalmologists. Lead the diagnosis and management plan Regularly evaluate treatment efficacy and adjust as needed"}
{"id": "article-151525_181", "title": "Sympathetic Ophthalmia -- Enhancing Healthcare Team Outcomes -- Rheumatologists or Immunologists", "content": "Assist with systemic immunosuppression Monitor for side effects of treatments", "contents": "Sympathetic Ophthalmia -- Enhancing Healthcare Team Outcomes -- Rheumatologists or Immunologists. Assist with systemic immunosuppression Monitor for side effects of treatments"}
{"id": "article-151525_182", "title": "Sympathetic Ophthalmia -- Enhancing Healthcare Team Outcomes -- Nurses", "content": "Provide patient education and post-treatment care instructions Monitor for signs of complications or side effects from medication", "contents": "Sympathetic Ophthalmia -- Enhancing Healthcare Team Outcomes -- Nurses. Provide patient education and post-treatment care instructions Monitor for signs of complications or side effects from medication"}
{"id": "article-151525_183", "title": "Sympathetic Ophthalmia -- Enhancing Healthcare Team Outcomes -- Pharmacists", "content": "Manage and advise on medication interactions Counsel patients on proper medication usage and potential side effects", "contents": "Sympathetic Ophthalmia -- Enhancing Healthcare Team Outcomes -- Pharmacists. Manage and advise on medication interactions Counsel patients on proper medication usage and potential side effects"}
{"id": "article-151525_184", "title": "Sympathetic Ophthalmia -- Enhancing Healthcare Team Outcomes -- Ethics and Strategy", "content": "Ensure informed consent\u00a0is obtained, especially when discussing the risks of bilateral eye involvement. Maintain patient confidentiality and autonomy in the management\u00a0plan", "contents": "Sympathetic Ophthalmia -- Enhancing Healthcare Team Outcomes -- Ethics and Strategy. Ensure informed consent\u00a0is obtained, especially when discussing the risks of bilateral eye involvement. Maintain patient confidentiality and autonomy in the management\u00a0plan"}
{"id": "article-151525_185", "title": "Sympathetic Ophthalmia -- Enhancing Healthcare Team Outcomes -- Communication and Coordination", "content": "Use clear, consistent communication across the care team. Establish a protocol for emergencies related to sudden vision changes or flare-ups.", "contents": "Sympathetic Ophthalmia -- Enhancing Healthcare Team Outcomes -- Communication and Coordination. Use clear, consistent communication across the care team. Establish a protocol for emergencies related to sudden vision changes or flare-ups."}
{"id": "article-151525_186", "title": "Sympathetic Ophthalmia -- Enhancing Healthcare Team Outcomes -- Patient Safety and Outcomes", "content": "Educate patients on signs of disease progression and when to seek immediate care. Implement safety checks to prevent medication errors.", "contents": "Sympathetic Ophthalmia -- Enhancing Healthcare Team Outcomes -- Patient Safety and Outcomes. Educate patients on signs of disease progression and when to seek immediate care. Implement safety checks to prevent medication errors."}
{"id": "article-151525_187", "title": "Sympathetic Ophthalmia -- Enhancing Healthcare Team Outcomes -- Team Performance", "content": "Hold regular team meetings to discuss patient progress and coordinate care. Provide continuous education on the latest research and treatments for sympathetic ophthalmia.", "contents": "Sympathetic Ophthalmia -- Enhancing Healthcare Team Outcomes -- Team Performance. Hold regular team meetings to discuss patient progress and coordinate care. Provide continuous education on the latest research and treatments for sympathetic ophthalmia."}
{"id": "article-151525_188", "title": "Sympathetic Ophthalmia -- Enhancing Healthcare Team Outcomes", "content": "Overall, each team member ensures comprehensive care, from prevention and early intervention to long-term management and monitoring of sympathetic ophthalmia. [3] [154] [155] [156] [157] [158] [159] [160]", "contents": "Sympathetic Ophthalmia -- Enhancing Healthcare Team Outcomes. Overall, each team member ensures comprehensive care, from prevention and early intervention to long-term management and monitoring of sympathetic ophthalmia. [3] [154] [155] [156] [157] [158] [159] [160]"}
{"id": "article-151525_189", "title": "Sympathetic Ophthalmia -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Sympathetic Ophthalmia -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}